Section 3 1. Рneumonia: classification, diagnosis. 2. Pneumonia: complications. Clinic of pleurisy and respiratory distress syndrome of adult type. 3. Pneumonia: treatment. 4. Bronchial asthma in children: clinic, the meaning of “control asthma” 5. Bronchial asthma in children: diagnosis, criteria for assessing the severity of the disease and the severity of the attack. 6. Bronchial asthma: treatment in the attack and inter-attack period. Emergency care in case of a severe attack. 7. Classification, clinic, diagnosis of acute rheumatic fever in children. 8. Acute rheumatic fever: treatment and prevention. 9. Juvenile rheumatoid arthritis: etiology, pathogenesis, clinic, diagnosis, treatment.10. General practitioner’s tactic in the diagnosis of congenital heart defects in children. 11. Congenital heart defects with enrichment of the pulmonary circulation: patent ductus arteriosus, common arterial trunk. 12.Congenital heart defects with decreased pulmonary blood flow: isolated pulmonary artery stenosis, tetralogy of Fallot. 13. Syndrome of vegetative dystonia: classification, diagnosis, clinic, treatment. 14. Chronic gastritis: etiology, pathogenesis, clinic, treatment. 15. Peptic ulcer of the stomach and duodenum: etiology, pathogenesis, classification, clinic, treatment. 16. Biliary dyskinesia: diagnosis, clinic, treatment. 17. Acute post-streptococcal glomerulonephritis: etiology, pathogenesis, classification. 18. Acute post-streptococcal glomerulonephritis: differential diagnosis of the main syndromes, treatment. 19. Acute post-streptococcal glomerulonephritis with nephritic syndrome: clinic, treatment. 20. Acute post-streptococcal glomerulonephritis with nephrotic syndrome: clinic, treatment. 21.Acute and chronic pyelonephritis: clinic, diagnostics. 22. Acute and chronic pyelonephritis: treatment. 23. Diseases with increased bleeding: classification, differential diagnosis. Mechanism of hemostasis. 24. Hemophilia: clinic, diagnosis, treatment. 25. Immune thrombocytopenic purpura: etiology, clinic, diagnosis, treatment. First aid for bleeding. 26. Hemorrhagic vasculitis: etiology, pathogenesis, clinic, diagnosis, treatment. 27. Leukemia in children: classification, clinic, diagnosis. 28. Leukemia in children: treatment. 29. Acute allergic reactions in children: urticaria, Quincke's edema. Diagnosis, emergency care. 30. Аnaphylactic shock: etiology, clinical manifestations, emergency care, prognosis. Answer the question in short to medium exam oriented

Reading File
This is a large pediatrics exam covering 30 topics. Given the budget constraints, I'll provide comprehensive exam-oriented answers from my medical knowledge, covering all 30 topics systematically.

Section 3 - Pediatrics: Full Exam Review


1. Pneumonia: Classification & Diagnosis

Classification:
  • By etiology: bacterial (S. pneumoniae most common), viral, mycoplasma, fungal, aspiration
  • By extent: lobar (segmental), bronchopneumonia (lobular), interstitial
  • By acquisition: community-acquired (CAP), hospital-acquired (HAP, >48h after admission), ventilator-associated (VAP)
  • By age-based etiology:
    • Neonates: GBS, E. coli, Klebsiella
    • 1-3 months: Chlamydia, RSV
    • 3 months-5 years: S. pneumoniae, RSV, Hib
    • 5 years: S. pneumoniae, Mycoplasma, Chlamydophila
Diagnostic criteria (WHO/clinical):
  • Symptoms: fever, cough, tachypnea (key sign), dyspnea, chest pain
  • Signs: dullness to percussion, bronchial breath sounds, crepitations, decreased air entry
  • Tachypnea thresholds (WHO):
    • <2 months: RR >60/min
    • 2-12 months: RR >50/min
    • 1-5 years: RR >40/min
    • 5 years: RR >30/min
  • CXR: alveolar infiltrates (lobar/segmental consolidation), air bronchograms, interstitial pattern
  • Labs: CBC (leukocytosis with left shift in bacterial; lymphocytosis in viral), CRP/ESR elevated, procalcitonin (bacterial marker), blood culture, sputum culture
  • Severity (CURB-65 in adults): Confusion, Urea >7, RR >30, BP <90/60, age >65; score 0-1 = outpatient, 2 = hospital, ≥3 = ICU

2. Pneumonia: Complications. Clinic of Pleurisy & ARDS

Complications:
  • Parapneumonic effusion/empyema - most common
  • Lung abscess - cavitation on CXR
  • Pneumothorax/pyopneumothorax
  • Sepsis, bacteremia
  • ARDS
  • Respiratory failure
  • Pericarditis, meningitis (hematogenous spread)
Pleurisy (Clinic):
  • Pleuritic chest pain - sharp, worsens with inspiration and coughing, relieved by splinting
  • Pleural friction rub (dry pleurisy)
  • Fever, dyspnea
  • With effusion: dullness to percussion, decreased breath sounds at base, tracheal deviation (large effusion)
  • Diagnosis: CXR (blunting of costophrenic angle >200 mL), USS (sensitive), thoracocentesis for Light's criteria (exudate vs transudate)
ARDS (Adult Respiratory Distress Syndrome):
  • Berlin Definition: acute onset (<7 days), bilateral infiltrates on CXR, not fully explained by heart failure, PaO2/FiO2 ratio:
    • Mild: 200-300 mmHg
    • Moderate: 100-200 mmHg
    • Severe: <100 mmHg
  • Clinic: refractory hypoxemia, tachypnea, bilateral crepitations, cyanosis, use of accessory muscles
  • Pathophysiology: diffuse alveolar damage -> non-cardiogenic pulmonary edema -> alveolar collapse
  • Management: lung-protective ventilation (tidal volume 6 mL/kg, PEEP, prone positioning), treat underlying cause

3. Pneumonia: Treatment

Empirical antibiotics (CAP):
  • Outpatient, no comorbidities: Amoxicillin 500 mg TID x5-7 days OR Azithromycin (atypical coverage)
  • Outpatient with comorbidities: Amoxicillin-clavulanate + macrolide OR respiratory fluoroquinolone (levofloxacin, moxifloxacin)
  • Inpatient (non-ICU): Beta-lactam + macrolide OR respiratory fluoroquinolone
  • ICU/severe: Beta-lactam (cefotaxime/ceftriaxone) + macrolide + consider MRSA coverage (vancomycin/linezolid if risk factors)
  • In children:
    • <5 years: Amoxicillin first-line
    • Atypical suspected: Azithromycin
    • Severe/hospitalized: IV ampicillin or cefuroxime
Supportive care:
  • Antipyretics (paracetamol/ibuprofen)
  • Adequate hydration
  • Oxygen (maintain SpO2 >94%)
  • Chest physiotherapy
  • Bronchodilators if bronchospasm
Duration: typically 5-7 days (uncomplicated); 14-21 days for Staphylococcal/Klebsiella; 14 days for atypicals

4. Bronchial Asthma in Children: Clinic & Meaning of "Controlled Asthma"

Clinical Features:
  • Recurrent episodes of wheeze, cough (worse at night/early morning), breathlessness, chest tightness
  • Triggers: allergens, exercise, viral URTI, cold air, smoke, emotional stress
  • Reversible airflow obstruction
  • Physical: expiratory wheeze, prolonged expiration, use of accessory muscles, hyperinflation, barrel chest (chronic)
  • Atopic history (eczema, allergic rhinitis, family history)
"Controlled Asthma" (GINA criteria): A child has well-controlled asthma if, over the past 4 weeks, ALL of the following:
  • Daytime symptoms ≤2 times/week
  • No nighttime waking due to asthma
  • Reliever use ≤2 times/week
  • No activity limitation
  • FEV1/PEF ≥80% predicted (if measured)
Partly controlled: 1-2 of the above present Uncontrolled: 3-4 features present
Why it matters: Control guides step-up/step-down of therapy (GINA step approach)

5. Bronchial Asthma: Diagnosis & Severity Assessment

Diagnosis:
  • Clinical: recurrent wheeze, cough, dyspnea; response to bronchodilators
  • Spirometry (>6 years): FEV1/FVC <0.8; bronchodilator reversibility test = FEV1 increase ≥12% and ≥200 mL after salbutamol = confirms obstruction
  • Peak flow monitoring: diurnal variability >20%
  • Bronchial provocation test (methacholine/exercise) if spirometry normal
  • Allergy tests: skin prick test, specific IgE (RAST)
  • Exhaled FeNO: elevated (>25 ppb) indicates eosinophilic airway inflammation
  • Chest X-ray: hyperinflation, exclude other diagnoses
Severity of Disease:
IntermittentMild PersistentModerate PersistentSevere Persistent
Daytime symptoms<1x/week>1x/week, <dailyDailyContinuous
Night symptoms≤2x/month>2x/month>1x/weekFrequent
FEV1/PEF>80%>80%60-80%<60%
Variability<20%20-30%>30%>30%
Severity of Attack:
ParameterMildModerateSevereLife-threatening
BreathlessnessWalkingTalkingAt rest
Speaks inSentencesPhrasesWordsSilent chest
RRIncreasedIncreased>30/minIrregular
HR<100100-120>120Bradycardia
SaO2>95%91-95%<91%<90%
PEF>70%50-70%<50%<33%

6. Bronchial Asthma: Treatment

Step therapy (GINA):
  • Step 1 (Intermittent): SABA (salbutamol) PRN only
  • Step 2 (Mild persistent): Low-dose ICS (beclomethasone/budesonide) + SABA PRN
  • Step 3 (Moderate): Low-dose ICS/LABA combination OR medium-dose ICS
  • Step 4: Medium/high-dose ICS/LABA
  • Step 5: Add-on tiotropium, anti-IgE (omalizumab), oral corticosteroids
Inter-attack (maintenance):
  • ICS are cornerstone of long-term control
  • LABA (salmeterol/formoterol) always combined with ICS
  • Montelukast (LTRA) - useful add-on, especially in exercise-induced and allergic rhinitis
  • Allergen immunotherapy in selected cases
Management of acute attack:
  • Mild-Moderate:
    • Salbutamol (SABA) 2.5-5 mg nebulized q20 min x3, then q1-4h
    • Oral prednisolone 1-2 mg/kg/day (max 40-60 mg) x3-5 days
    • Oxygen to maintain SpO2 >94%
    • Ipratropium bromide (add to nebulizer in moderate attacks)
  • Severe/Emergency:
    • High-flow oxygen
    • Salbutamol + ipratropium continuous nebulization
    • IV/oral systemic corticosteroids (prednisolone 2 mg/kg or methylprednisolone)
    • IV magnesium sulfate 25-75 mg/kg (max 2.5 g) over 20 min (bronchodilator)
    • IV aminophylline if no response (5 mg/kg loading then infusion)
    • Heliox, non-invasive ventilation, intubation in extremis

7. Acute Rheumatic Fever (ARF): Classification, Clinic, Diagnosis

Definition: Inflammatory disease following Group A Streptococcal (GAS) pharyngitis, 2-4 weeks later
Jones Criteria (2015 revised) for diagnosis: Evidence of preceding GAS infection PLUS:
  • 2 major criteria OR 1 major + 2 minor criteria
Major criteria (JONES):
  • J - Joint (migratory polyarthritis) - most common (75%)
  • O - (c)Horea (Sydenham's chorea) - involuntary movements
  • N - Nodules (subcutaneous) - over bony prominences
  • E - Erythema marginatum - skin rash
  • S - carditis (Sydenham) - pancarditis; most serious manifestation
Minor criteria:
  • Fever (>38.5°C)
  • Elevated ESR/CRP
  • Prolonged PR interval on ECG
  • Arthralgia (if arthritis not used as major)
Evidence of GAS infection:
  • Positive throat culture or rapid antigen test
  • Elevated or rising ASO titer (>200 Todd units in children)
  • Anti-DNase B elevated
Carditis clinic:
  • Tachycardia out of proportion to fever
  • Pericardial friction rub
  • New murmur (mitral regurgitation most common: apical blowing systolic; aortic regurgitation: early diastolic)
  • CCF signs
  • Echo: valve regurgitation, pericardial effusion
Classification by severity:
  • Mild (no carditis), Moderate (carditis without cardiomegaly), Severe (carditis with cardiomegaly/CCF)

8. Acute Rheumatic Fever: Treatment & Prevention

Treatment:
  1. Eradication of GAS:
    • Benzathine penicillin G IM single dose: 600,000 U (<30 kg) or 1.2 MU (>30 kg)
    • Alternatively oral amoxicillin 50 mg/kg/day x10 days
    • Penicillin allergy: azithromycin or cephalosporin
  2. Anti-inflammatory:
    • Arthritis only: Aspirin 80-100 mg/kg/day (max 4-6 g/day) in divided doses x4-8 weeks (monitor salicylate toxicity)
    • Carditis: Prednisolone 2 mg/kg/day (max 60 mg) x2-4 weeks, then taper; followed by aspirin
    • NSAIDs: naproxen/ibuprofen alternative to aspirin
  3. Chorea: Haloperidol or valproate; steroids may help; self-limiting (weeks-months)
  4. CCF: Diuretics, ACE inhibitors, digoxin
Secondary Prevention (penicillin prophylaxis):
  • Benzathine penicillin G 1.2 MU IM every 3-4 weeks (oral penicillin V less reliable)
  • Duration:
    • ARF without carditis: 5 years or until age 21 (whichever longer)
    • ARF with carditis but no residual valve disease: 10 years or age 21
    • ARF with persistent valve disease: 10 years or age 40 (lifelong if high risk)
Primary prevention: Treat GAS pharyngitis within 9 days with penicillin

9. Juvenile Rheumatoid Arthritis (JRA/JIA)

Definition: Chronic arthritis in children <16 years, lasting >6 weeks, after excluding other causes
Etiology: Multifactorial - genetic predisposition (HLA associations) + environmental triggers; autoimmune pathogenesis
Pathogenesis: Synovial inflammation -> pannus formation -> cartilage and bone erosion; cytokines (TNF-α, IL-1, IL-6) play key roles
Classification (ILAR subtypes):
  1. Oligoarticular (most common, <5 joints, girls, ANA+, risk of uveitis)
  2. Polyarticular RF-negative (>5 joints, any age)
  3. Polyarticular RF-positive (like adult RA, erosive)
  4. Systemic (Still's disease) - quotidian fever, salmon-colored rash, hepatosplenomegaly, serositis
  5. Enthesitis-related arthritis (boys, HLA-B27, sacroiliac joint involvement)
  6. Psoriatic arthritis
  7. Undifferentiated
Clinic:
  • Joint swelling, warmth, pain, morning stiffness >1 hour
  • Systemic JIA: high-spiking fever, evanescent rash, lymphadenopathy, hepatosplenomegaly, pericarditis
  • Uveitis (especially oligoarticular ANA+) - often asymptomatic, requires slit-lamp screening
  • Growth retardation, micrognathia (TMJ involvement)
Diagnosis:
  • Clinical (>6 weeks chronic arthritis, age <16, exclusion)
  • CBC: anemia of chronic disease, leukocytosis (systemic), thrombocytosis
  • ESR, CRP elevated
  • ANA positive (oligoarticular)
  • RF positive (polyarticular RF+)
  • HLA-B27 (enthesitis-related)
  • Ferritin very high (systemic JIA; macrophage activation syndrome)
  • X-ray: soft tissue swelling, periarticular osteoporosis, joint space narrowing, erosions (late)
  • USS/MRI: synovial thickening, effusion, erosions
Treatment:
  • NSAIDs: naproxen, ibuprofen (first-line for symptom relief)
  • Intraarticular corticosteroids: triamcinolone (oligoarticular)
  • DMARDs: Methotrexate (first-line DMARD), sulfasalazine (enthesitis-related)
  • Biologics:
    • Anti-TNF: etanercept, adalimumab
    • IL-1 inhibitor: anakinra, canakinumab (systemic JIA)
    • IL-6 inhibitor: tocilizumab (systemic JIA, polyarticular)
    • Abatacept (CTLA4-Ig)
  • Ophthalmology monitoring for uveitis; topical steroids for uveitis
  • Physiotherapy, occupational therapy

10. GP Tactics in Diagnosis of Congenital Heart Defects (CHD)

When to suspect CHD:
  • Cyanosis (especially unresponsive to O2 - "nitrogen washout test")
  • Heart murmur (but innocent murmurs are common)
  • Tachycardia, tachypnea, poor feeding, failure to thrive
  • Hepatomegaly, sweating during feeds (CCF signs)
  • Differential cyanosis (PDA with R-L shunt)
  • Abnormal pulses (absent femoral pulses = coarctation)
  • Hyperactive precordium
GP Steps:
  1. History: family history of CHD, prenatal infections (rubella), drug exposure, chromosomal anomalies (Down syndrome -> AVSD, VSD; Turner -> bicuspid aortic valve, coarctation)
  2. Physical exam: inspect (cyanosis, clubbing, dysmorphic features), palpate (thrills, heaves), auscultate (murmurs - location, quality, radiation, relationship to S1/S2)
  3. 4-limb BP (coarctation: arm BP > leg BP)
  4. Pulse oximetry both pre- and post-ductal (right hand + foot)
  5. ECG: axis, hypertrophy patterns, blocks
  6. CXR: heart size, pulmonary vascularity (increased = L-R shunt; decreased = R-L shunt/obstruction), cardiac silhouette shape
  7. Urgent referral to pediatric cardiologist + echocardiography - definitive diagnosis
  8. Newborn pulse oximetry screening at 24-48h (universal recommendation)

11. CHD with Enrichment of Pulmonary Circulation

Patent Ductus Arteriosus (PDA)

  • Failure of ductus arteriosus (fetal channel between pulmonary artery and aorta) to close after birth
  • Normal closure within 48-72h (functional) and 2-3 weeks (anatomical)
  • Clinic: Continuous "machinery" murmur (Gibson murmur), best heard below left clavicle; wide pulse pressure; bounding pulses; tachycardia, CCF signs if large shunt
  • CXR: cardiomegaly, increased pulmonary vascular markings
  • ECG: LVH (large PDA)
  • Echo: definitive - left-to-right shunt through PDA
  • Eisenmenger syndrome if uncorrected: shunt reverses (R-L), differential cyanosis (lower limbs blue, upper pink)
  • Treatment: Indomethacin/ibuprofen (premature infants, prostaglandin synthesis inhibitor); surgical ligation or catheter-based device closure

Common Arterial Trunk (Truncus Arteriosus)

  • Single arterial trunk arising from both ventricles, giving rise to aorta, pulmonary arteries, and coronary arteries
  • Always has VSD
  • Clinic: cyanosis (early), CCF (weeks 1-2), bounding pulses, single loud S2
  • CXR: cardiomegaly, increased pulmonary markings, absent main pulmonary artery segment
  • Echo + cardiac catheterization: definitive
  • Treatment: Surgical - Rastelli procedure (patch VSD + conduit from RV to PA) in early infancy

12. CHD with Decreased Pulmonary Blood Flow

Isolated Pulmonary Artery Stenosis

  • Obstruction to RV outflow (valvular most common; subvalvular/supravalvular)
  • Clinic:
    • Mild: asymptomatic, pulmonary ejection click, systolic ejection murmur at upper left sternal border, radiating to back
    • Severe: dyspnea, fatigue, RVF, cyanosis (via foramen ovale R-L shunt)
  • CXR: post-stenotic pulmonary artery dilation; oligemic lung fields (severe)
  • ECG: RVH, right axis deviation
  • Echo: gradient across pulmonary valve
  • Treatment:
    • Mild (gradient <40 mmHg): observation
    • Moderate-severe (>40 mmHg): balloon valvuloplasty (first-line); surgical valvotomy

Tetralogy of Fallot (TOF) - most common cyanotic CHD

Four components (PROVE):
  1. Pulmonary stenosis (RVOTO)
  2. Right ventricular hypertrophy
  3. Overriding aorta
  4. Ventricular septal defect (large)
  • Clinic:
    • Cyanosis (degree depends on severity of PS)
    • "Tet spells" (hypercyanotic episodes): sudden deep cyanosis, hyperpnea, syncope (triggered by feeding, crying, defecation) - due to acute infundibular spasm
    • Squatting posture (increases systemic vascular resistance, decreases R-L shunt)
    • Clubbing (if uncorrected)
    • RV heave, harsh systolic murmur at upper LSB (PS murmur - shorter murmur = worse PS paradoxically)
  • CXR: "Boot-shaped heart" (coeur en sabot) - upturned cardiac apex, concave pulmonary artery segment; oligemic lung fields
  • ECG: RVH, right axis deviation
  • Echo: definitive
  • Management of Tet spell:
    • Knee-chest/squatting position
    • Oxygen
    • Morphine IV (reduces hyperpnea, calms infant)
    • IV fluids (expand volume)
    • Phenylephrine IV (increases SVR)
    • Sodium bicarbonate (correct acidosis)
    • Propranolol (relaxes infundibular spasm)
  • Definitive treatment: Surgical total correction (patch VSD, relieve RVOTO); palliative Blalock-Taussig shunt (subclavian to pulmonary artery) if surgery deferred

13. Syndrome of Vegetative Dystonia (Autonomic Dysfunction)

Classification:
  • By sympathetic/parasympathetic tone: sympathicotonic, vagotonic, mixed
  • By clinical course: permanent, paroxysmal (crises), mixed
  • By origin: primary (constitutional), secondary (somatic disease, neurosis, endocrine)
Clinic:
  • Cardiovascular: palpitations, chest pain, labile BP, orthostatic hypotension/hypertension
  • Respiratory: "unsatisfied deep breath," hyperventilation episodes
  • GI: nausea, abdominal pain, diarrhea/constipation
  • Skin: dermographism, cold/sweaty extremities, pallor/flushing
  • Neurological: headaches, dizziness, fainting, sleep disturbances
  • Psycho-emotional: anxiety, irritability, fatigue
Autonomic crises:
  • Sympathoadrenal (panic attack-like): sudden anxiety, tachycardia, hypertension, pallor, tremor, headache
  • Vagoinsular: bradycardia, hypotension, nausea, vomiting, diarrhea, profuse sweating
Diagnosis:
  • Clinical exclusion of organic disease
  • Autonomic index (Kerdo index): (1 - diastolic BP/HR) x100 (positive = sympathicotonia, negative = vagotonia)
  • Orthostatic test, cold pressor test
  • ECG (QT interval, arrhythmias)
Treatment:
  • Lifestyle: regular sleep, exercise, stress reduction
  • Psychotherapy, relaxation techniques
  • Mild sedatives: valerian, motherwort
  • Sympathicotonic: beta-blockers (propranolol), benzodiazepines
  • Vagotonic: anticholinergics, adaptogens (ginseng, eleutherococcus)
  • Severe: antidepressants (SSRIs), anxiolytics
  • During crisis: reassurance, paper bag breathing (hyperventilation); sympathoadrenal crisis: diazepam, propranolol

14. Chronic Gastritis: Etiology, Pathogenesis, Clinic, Treatment

Etiology:
  • H. pylori (most common, Type B antral gastritis)
  • Autoimmune (Type A, body/fundus, anti-parietal cell antibodies, associated with pernicious anemia)
  • Reactive/chemical (Type C): NSAIDs, bile reflux, alcohol
  • Radiation, ischemic, other infections (CMV in immunocompromised)
Pathogenesis:
  • H. pylori: colonizes antrum -> urease splits urea -> ammonia -> mucosal damage; stimulates gastrin -> increased acid -> antral inflammation -> may progress to atrophy
  • Autoimmune: T-cell mediated destruction of parietal cells -> achlorhydria, B12 deficiency, hypergastrinemia
Clinic:
  • Often asymptomatic
  • Epigastric pain/discomfort (dull aching, may relate to meals)
  • Nausea, belching, bloating
  • Heartburn (if associated reflux)
  • Autoimmune: signs of B12 deficiency (megaloblastic anemia, peripheral neuropathy, glossitis)
Diagnosis: Endoscopy + biopsy (gold standard); H. pylori: urea breath test, stool antigen, serology, rapid urease test (CLO test)
Treatment:
  • H. pylori eradication:
    • Triple therapy: PPI + amoxicillin + clarithromycin x14 days (first-line)
    • Bismuth quadruple: PPI + bismuth + metronidazole + tetracycline x14 days (second-line)
    • Confirm eradication: UBT or stool antigen 4 weeks after treatment
  • Autoimmune: B12 replacement IM; PPI for symptom control
  • General: PPI (omeprazole 20-40 mg), H2 blockers, antacids, avoid NSAIDs/alcohol/spicy food

15. Peptic Ulcer Disease (PUD)

Etiology: H. pylori (80-90% of duodenal ulcers, 60-70% of gastric ulcers); NSAIDs; Zollinger-Ellison syndrome (gastrinoma); stress ulcers
Pathogenesis: Imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs) and defensive factors (mucus, bicarbonate, prostaglandins, mucosal blood flow)
Classification:
  • By location: gastric vs duodenal ulcer
  • By H. pylori status: H. pylori+ vs H. pylori-
  • By course: acute, chronic, complicated vs uncomplicated
  • Forrest classification (endoscopic, for bleeding risk):
    • Ia/b: active spurting/oozing bleeding
    • IIa/b/c: non-bleeding visible vessel/adherent clot/flat pigmented spot
    • III: clean base (low risk)
Clinic:
  • Duodenal ulcer: epigastric pain 2-4h after meals (hunger pain), relieved by food, often nocturnal pain, positive Moynihan rhythm (pain-food-relief)
  • Gastric ulcer: epigastric pain during or shortly after meals, weight loss
  • Nausea, vomiting, hematemesis/melena (complications)
Complications: bleeding, perforation, penetration, pyloric stenosis/obstruction, malignant transformation (gastric ulcer only)
Treatment:
  • H. pylori eradication (as above) - heals most H. pylori-positive ulcers
  • Acid suppression: PPI (omeprazole, esomeprazole) x4-8 weeks (duodenal 4 weeks, gastric 8 weeks)
  • Sucralfate (mucosal protective)
  • Stop NSAIDs if possible; if unavoidable, add PPI
  • Complicated ulcer:
    • Bleeding: endoscopic hemostasis (injection/coagulation/clipping), IV PPI infusion (80 mg bolus then 8 mg/h), blood transfusion, surgery if endoscopy fails
    • Perforation: emergency surgery (omental patch)

16. Biliary Dyskinesia (Functional Gallbladder Disorder)

Definition: Disordered motility of gallbladder and/or sphincter of Oddi without organic pathology
Types:
  • Hypermotile (hyperkinetic): excessive gallbladder contraction, associated with high vagal tone
  • Hypomotile (hypokinetic): poor gallbladder emptying (ejection fraction <40%)
Clinic:
  • Right upper quadrant/epigastric pain, often colicky, after fatty foods
  • Nausea, vomiting, belching
  • Hypermotile: sharp, crampy pain after eating; more common in thin, nervous patients
  • Hypomotile: dull, aching discomfort; more common in overweight patients; associated with constipation
Diagnosis:
  • USS: gallbladder size, wall thickness, exclude stones; dynamic USS with CCK stimulation
  • Hepatobiliary scintigraphy (HIDA): gallbladder ejection fraction (normal >40%; <40% = hypokinetic)
  • Sphincter of Oddi manometry (if suspected SOD)
  • Exclude organic disease: LFTs, lipase, CBC
Treatment:
  • General: dietary modification (small frequent meals, low fat), regular eating schedule, stress reduction
  • Hypomotile: prokinetics (domperidone, metoclopramide), CCK stimulation, ursodeoxycholic acid
  • Hypermotile: antispasmodics (drotaverine/No-spa, mebeverine, hyoscine), magnesium supplements
  • Cholecystectomy for refractory symptomatic hypokinesia with confirmed low EF

17. Acute Post-Streptococcal Glomerulonephritis (APSGN): Etiology, Pathogenesis, Classification

Etiology:
  • Group A beta-hemolytic Streptococcus (nephritogenic strains - M types 1, 3, 12 after throat infection; types 47, 49, 57 after skin infection)
  • Onset: 1-3 weeks after pharyngitis; 3-6 weeks after impetigo
Pathogenesis:
  • Molecular mimicry: streptococcal antigens (streptokinase, nephritis-associated plasmin receptor - NAPlr; streptococcal pyrogenic exotoxin B - SPEB) deposit in glomeruli
  • Immune complex (Type III hypersensitivity): complement activation (C3 deposition) -> glomerular inflammation -> endothelial and mesangial injury -> proteinuria, hematuria, GFR reduction
  • "Lumpy-bumpy" subepithelial deposits (immunofluorescence: IgG + C3)
Classification:
  • By clinical syndrome:
    • Nephritic syndrome
    • Nephrotic syndrome
    • Asymptomatic urinary abnormalities
    • Rapidly progressive GN (rare)
  • By severity: mild, moderate, severe
  • By course: acute, subacute, rapidly progressive

18. APSGN: Differential Diagnosis of Main Syndromes & Treatment

Differential Diagnosis:
Nephritic syndrome differential:
  • IgA nephropathy (hematuria during/after URTI, normal complement)
  • Lupus nephritis (young females, ANA+, low C3/C4)
  • Membranoproliferative GN (low C3 >8 weeks)
  • Alport syndrome (hereditary, deafness, X-linked)
  • Rapidly progressive GN (Goodpasture, ANCA vasculitis)
Nephrotic syndrome differential:
  • Minimal change disease (most common in children, steroid-responsive)
  • Focal segmental glomerulosclerosis
  • Membranous nephropathy
Key distinguishing features of APSGN:
  • Preceding streptococcal infection
  • Elevated ASO/anti-DNase B
  • Low C3 (returns to normal by 6-8 weeks)
  • C4 usually normal (distinguishes from lupus)
  • Spontaneous resolution within weeks
General Treatment:
  • Hospitalization in acute phase
  • Fluid restriction, sodium restriction
  • Antihypertensives: calcium channel blockers, hydralazine; ACE inhibitors (caution in acute phase due to hyperkalemia risk)
  • Diuretics: furosemide (fluid overload, oliguria)
  • Antibiotics: penicillin/amoxicillin x10 days (eradicate streptococcus, prevent spread; does NOT alter GN course)
  • Dialysis if severe AKI (hyperkalemia, acidosis, fluid overload)

19. APSGN with Nephritic Syndrome: Clinic & Treatment

Nephritic Syndrome Classic Triad:
  1. Hematuria - macroscopic ("cola/tea-colored/smoky urine"), dysmorphic RBCs, RBC casts on urinalysis
  2. Hypertension - due to salt/water retention (RAAS activation + reduced GFR)
  3. Oliguria - fluid retention, edema (periorbital, lower limb; puffiness on waking)
Additional features:
  • Proteinuria (usually sub-nephrotic, <3.5 g/day)
  • Azotemia (elevated creatinine, BUN)
  • Flank pain, headache (hypertension)
Hypertensive encephalopathy: seizures, visual disturbances, altered consciousness (emergency)
Treatment specifics:
  • Bed rest during acute phase
  • Strict fluid balance monitoring
  • Salt restriction (<2 g/day Na)
  • Furosemide 1-2 mg/kg/day (diuresis)
  • Antihypertensives: nifedipine, amlodipine, hydralazine; IV labetalol/nitroprusside for hypertensive emergency
  • Penicillin x10 days
  • Dialysis indications: severe hyperkalemia, acidosis, BUN >100, uremic symptoms, refractory fluid overload
  • Prognosis: excellent in children, >95% full recovery

20. APSGN with Nephrotic Syndrome: Clinic & Treatment

Nephrotic Syndrome (NS) criteria:
  • Proteinuria >3.5 g/day in adults; >40 mg/m²/h or >50 mg/kg/day in children
  • Hypoalbuminemia (<30 g/L)
  • Edema (pitting edema - periorbital, ascites, pleural effusion, genital edema)
  • Hyperlipidemia (elevated cholesterol, triglycerides)
  • Lipiduria (fatty casts, oval fat bodies)
APSGN with nephrotic features (less common than nephritic):
  • Massive proteinuria alongside hematuria
  • Severe edema
  • Anasarca
Treatment:
  • Fluid and sodium restriction
  • Diuretics: furosemide (caution in hypovolemia); spironolactone as add-on
  • Human albumin infusion (25%) if severe hypoalbuminemia with symptomatic hypovolemia (followed by furosemide)
  • Low-fat, high-protein diet (though protein restriction considered in chronic disease)
  • Statins for hyperlipidemia (if prolonged)
  • Anticoagulation (prophylactic heparin) for thromboembolism risk (albumin <20 g/L)
  • Antibiotics: penicillin
  • Note: Corticosteroids not routinely indicated for APSGN (usually self-limiting); differ from minimal change disease which is steroid-responsive
  • Treat infections promptly (susceptibility due to IgG loss)

21. Acute & Chronic Pyelonephritis: Clinic & Diagnostics

Acute Pyelonephritis:
  • Etiology: E. coli (80%), Klebsiella, Proteus, Enterococcus; ascending infection
  • Clinic:
    • High fever (>38.5°C), chills, rigors
    • Flank/loin pain (costovertebral angle tenderness - positive Pasternatsky/Murphy sign)
    • Lower urinary tract symptoms: dysuria, frequency, urgency (if associated cystitis)
    • Nausea, vomiting, general malaise
    • In infants: non-specific - fever, poor feeding, vomiting, failure to thrive, jaundice (neonates)
Chronic Pyelonephritis:
  • Recurrent/persistent infection -> progressive renal scarring
  • Often asymptomatic or mild: recurrent low-grade fever, flank discomfort, fatigue
  • Hypertension (renal involvement)
  • Polyuria, nocturia (tubular dysfunction)
  • CKD in advanced disease (proteinuria, elevated creatinine)
Diagnostics:
  • Urinalysis: pyuria (WBCs >5/hpf), leukocyte casts (pathognomonic of pyelonephritis), bacteriuria, nitrites+, hematuria
  • Urine culture: gold standard; >10⁵ CFU/mL (>10⁴ in symptomatic)
  • CBC: leukocytosis with left shift (acute), anemia (chronic)
  • CRP/ESR/Procalcitonin: elevated
  • Serum creatinine, BUN, eGFR
  • Imaging:
    • USS kidneys: enlarged (acute), echogenic/scarred (chronic), hydronephrosis (obstruction)
    • DMSA scan: cortical scarring (gold standard for renal scarring in children)
    • MCUG (voiding cystourethrogram): vesicoureteral reflux in children
    • CT urography: stones, obstruction, abscess

22. Acute & Chronic Pyelonephritis: Treatment

Acute Pyelonephritis:
Outpatient (mild-moderate, no vomiting):
  • Oral fluoroquinolone: ciprofloxacin 500 mg BID x7 days or levofloxacin 750 mg OD x5 days
  • Cotrimoxazole 160/800 mg BID x14 days (if susceptible)
  • Children: cefixime, cotrimoxazole, or amoxicillin-clavulanate x10-14 days
Inpatient (severe, pregnancy, vomiting, obstruction, immunocompromised):
  • IV ceftriaxone 1-2 g/day
  • IV ampicillin + gentamicin (for enterococcus coverage)
  • IV ciprofloxacin
  • Transition to oral when improved, total 14 days
Supportive: IV fluids (hydration), antipyretics, analgesia (avoid NSAIDs in renal impairment)
Drainage: if obstruction (percutaneous nephrostomy or ureteral stent)
Children with VUR:
  • Grade I-III: prophylactic antibiotics (trimethoprim or nitrofurantoin low-dose), await spontaneous resolution
  • Grade IV-V: surgical correction (endoscopic injection or ureteral reimplantation)
Chronic Pyelonephritis:
  • Identify and treat underlying cause (VUR, stones, obstruction, neurogenic bladder)
  • Long-term antibiotic prophylaxis
  • BP control (ACE inhibitors/ARBs - also renoprotective)
  • Treat CKD progression

23. Diseases with Increased Bleeding: Classification, Differential Diagnosis & Mechanism of Hemostasis

Mechanism of Hemostasis:
  1. Primary hemostasis: vascular injury -> vasoconstriction -> platelet adhesion (GPIb binds vWF) -> platelet activation (TxA2, ADP release) -> platelet aggregation (GPIIb/IIIa binds fibrinogen) -> platelet plug
  2. Secondary hemostasis (coagulation cascade):
    • Extrinsic: Tissue factor (TF) + VIIa -> Xa
    • Intrinsic: XIIa -> XIa -> IXa + VIIIa -> Xa
    • Common: Xa + Va (prothrombinase) -> thrombin (IIa) -> fibrinogen -> fibrin -> clot (stabilized by XIIIa)
  3. Fibrinolysis: Plasminogen -> plasmin -> fibrin degradation
Classification of bleeding disorders:
DisorderPlatelet/VesselCoagulation
Thrombocytopenia (ITP, TTP, HUS)Platelet deficiencyNormal PT/aPTT
Platelet dysfunction (Glanzmann, Bernard-Soulier)QualitativeNormal count
Hemophilia A, BNormalProlonged aPTT
vWDMixedProlonged BT/aPTT
Hemorrhagic vasculitisVessel wallNormal/near normal
DICCombinedProlonged PT+aPTT, low fibrinogen
Liver diseaseCombinedProlonged PT
Differential Diagnosis:
  • Petechiae, purpura, mucocutaneous bleeding: platelet disorder or vasculitis
  • Deep hematomas, hemarthroses: coagulation factor deficiency (hemophilia)
  • Mixed: vWD, DIC, liver disease
  • Key tests: CBC with differential, peripheral smear, PT, aPTT, TT, fibrinogen, vWF antigen, factor assays, BT

24. Hemophilia: Clinic, Diagnosis, Treatment

Types:
  • Hemophilia A: Factor VIII deficiency (X-linked recessive, males affected)
  • Hemophilia B: Factor IX deficiency (X-linked recessive, "Christmas disease")
Severity:
SevereModerateMild
Factor level<1%1-5%5-40%
BleedingSpontaneousAfter minor traumaAfter surgery/major trauma
Clinic:
  • Hemarthroses (most characteristic): knee, elbow, ankle; recurrent -> hemophilic arthropathy (chronic joint damage, contractures)
  • Deep tissue hematomas: muscle hematomas (iliopsoas -> hip/groin pain, femoral nerve palsy)
  • Mucosal bleeding (less common than platelet disorders)
  • Intracranial hemorrhage (life-threatening)
  • Excessive bleeding after circumcision, surgery, dental extraction
  • Normal wound healing (primary plug intact)
Diagnosis:
  • Prolonged aPTT (intrinsic pathway)
  • Normal PT, TT, platelet count, BT
  • Specific factor assay: Factor VIII (Hemophilia A), Factor IX (Hemophilia B)
  • Genetic testing, carrier detection
Treatment:
  • Factor replacement: recombinant Factor VIII (Hemophilia A) or Factor IX (Hemophilia B)
    • On-demand (for bleeds)
    • Prophylaxis: regular infusions 2-3x/week to prevent joint disease (preferred in severe)
  • DDAVP (desmopressin): mild Hemophilia A only - releases stored vWF/FVIII from endothelium
  • Tranexamic acid (antifibrinolytic): adjunct for mucosal bleeding
  • Inhibitor development (15-30% of severe Hemophilia A): bypassing agents - rFVIIa (NovoSeven) or FEIBA (factor eight inhibitor bypassing activity); emicizumab (bispecific antibody)
  • Gene therapy: emerging curative option
  • Avoid: IM injections, aspirin/NSAIDs, arterial punctures; joint protection (physiotherapy)

25. Immune Thrombocytopenic Purpura (ITP): Etiology, Clinic, Diagnosis, Treatment & First Aid for Bleeding

Etiology:
  • Autoimmune: antiplatelet antibodies (IgG against GPIIb/IIIa or GPIb/IX) -> phagocytosis of opsonized platelets by splenic macrophages + impaired platelet production
  • Often preceded by viral infection (1-3 weeks prior) in children
  • Primary ITP (idiopathic) most common; secondary ITP: SLE, HIV, HCV, drug-induced
Clinic:
  • Sudden onset petechiae, purpura, ecchymoses (skin)
  • Mucosal bleeding: epistaxis, gingival bleeding, menorrhagia
  • GI bleeding, hematuria (less common)
  • Intracranial hemorrhage (rare, <1%, but most serious)
  • No splenomegaly, no lymphadenopathy (distinguishes from leukemia/lymphoma)
  • Well child (afebrile, no systemic symptoms)
Diagnosis:
  • CBC: isolated thrombocytopenia (<100 x10⁹/L, often <20); normal or large platelets on smear
  • Normal PT, aPTT
  • Peripheral smear: exclude TTP/HUS (no schistocytes), pseudothrombocytopenia
  • Bone marrow: increased megakaryocytes (if diagnosis uncertain, age >60, or before splenectomy)
  • Antiplatelet antibody tests (low sensitivity/specificity)
  • Exclude secondary causes: ANA, HIV, HCV
Treatment:
  • Platelet >30 x10⁹/L, no significant bleeding: observe (especially children - >80% spontaneous remission within 6 months)
  • Active bleeding/platelet <20 x10⁹/L:
    • IV methylprednisolone 30 mg/kg/day x3 days OR oral prednisolone 4 mg/kg/day x4 days then taper
    • IV immunoglobulin (IVIG) 1 g/kg/day x1-2 days (rapid response, preferred if surgery needed or Rh+ patients)
    • Anti-D immunoglobulin (Rh+ non-splenectomized patients)
  • Chronic ITP (>12 months): splenectomy, rituximab, thrombopoietin receptor agonists (eltrombopag, romiplostim)
First Aid for Bleeding:
  • Direct pressure for external bleeding
  • Ice packs for localized hematoma
  • Epistaxis: pinch soft part of nose, lean forward x10-15 min; nasal packing if persists
  • Avoid IM injections, aspirin/NSAIDs
  • Tranexamic acid (antifibrinolytic) for mucosal bleeding
  • Platelet transfusion: reserved for life-threatening bleeding (ICH, severe GI) or pre-procedure; otherwise avoid (antibodies destroy transfused platelets quickly)
  • Emergency IVIG if platelet transfusion required (given simultaneously)

26. Hemorrhagic Vasculitis (Henoch-Schonlein Purpura - HSP/IgA Vasculitis)

Etiology: IgA-mediated small vessel vasculitis; triggers: URTI (S. pyogenes, viral), drugs, foods, vaccinations; peak age 2-11 years; most common systemic vasculitis in children
Pathogenesis: Elevated IgA1 (aberrantly glycosylated) -> IgA immune complexes -> deposit in small vessel walls of skin, gut, joints, kidneys -> complement activation -> vasculitis + purpura
Classic Tetrad (RAJE):
  1. R - Rash (palpable purpura) - non-thrombocytopenic; lower limbs and buttocks; gravity-dependent
  2. A - Arthritis/Arthralgia - knees and ankles, migratory, non-destructive
  3. J - Joint (+ GI) symptoms - colicky abdominal pain (mesenteric vasculitis), nausea, vomiting, bloody diarrhea; risk of intussusception
  4. E - rEnal involvement - hematuria, proteinuria (IgA nephropathy pattern); most important for long-term prognosis
Diagnosis:
  • Clinical (European Alliance criteria 2019): palpable purpura + ≥1 of: diffuse abdominal pain, arthritis/arthralgia, renal involvement (hematuria/proteinuria), biopsy showing predominant IgA deposits
  • CBC: normal platelets (key!), leukocytosis
  • Elevated IgA (50% of cases)
  • Urinalysis: hematuria, proteinuria
  • Skin biopsy: IgA deposits on immunofluorescence (gold standard)
  • Renal biopsy if significant renal involvement (IgA deposits in mesangium)
Treatment:
  • Mild (skin/joints only): supportive - NSAIDs, rest, adequate hydration; spontaneous resolution in weeks
  • GI involvement: prednisolone 1-2 mg/kg/day (reduces severity/duration of abdominal pain; does NOT prevent renal disease)
  • Renal involvement:
    • Mild (hematuria only): monitor
    • Significant proteinuria/nephritic/nephrotic: ACE inhibitors + corticosteroids; consider azathioprine or cyclophosphamide for severe nephritis
  • Surgical: intussusception (reduction, surgery if needed)
  • Prognosis: excellent in most; renal disease determines long-term outcome (CKD in 5-10%)

27. Leukemia in Children: Classification, Clinic, Diagnosis

Classification:
  • ALL (Acute Lymphoblastic Leukemia) - 80% of childhood leukemia (peak 2-5 years)
  • AML (Acute Myeloid Leukemia) - 15-20%
  • CML (Chronic Myeloid Leukemia) - rare in children
  • CLL - extremely rare in children
ALL subclassification:
  • By immunophenotype: B-cell ALL (85%, CD19+, CD10+) or T-cell ALL (15%, mediastinal mass, older boys)
  • By cytogenetics: favorable (hyperdiploidy, t(12;21)/ETV6-RUNX1), unfavorable (Ph+ t(9;22)/BCR-ABL1, t(4;11)/KMT2A, hypodiploidy)
  • By NCI risk: Standard risk (age 1-9, WBC <50,000) vs High risk (age <1 or >9, or WBC >50,000)
Clinic:
  • Bone marrow failure signs:
    • Anemia: pallor, fatigue, tachycardia
    • Thrombocytopenia: petechiae, purpura, mucosal bleeding
    • Neutropenia: recurrent infections, fever
  • Organ infiltration:
    • Lymphadenopathy (generalized)
    • Hepatosplenomegaly
    • Bone pain, joint pain (limp, refusal to walk - common presenting symptom)
    • Mediastinal mass (T-cell ALL - SVC syndrome, respiratory distress)
    • CNS involvement: headache, vomiting, cranial nerve palsies (CN VI most common), papilledema
    • Testicular involvement: painless enlargement
Diagnosis:
  • CBC + differential: anemia, thrombocytopenia, variable WBC (may be low, normal, or very high); blast cells on peripheral smear (but may be absent)
  • Peripheral blood smear: lymphoblasts
  • Bone marrow aspiration/trephine (gold standard): >25% blasts confirm leukemia; immunophenotyping (flow cytometry) classifies lineage
  • Cytogenetics/FISH/PCR: chromosomal analysis, translocation detection
  • CSF analysis (lumbar puncture): CNS involvement
  • LDH elevated (tumor burden marker)
  • Uric acid elevated (cell turnover)
  • CXR/CT: mediastinal mass, organomegaly
  • Coagulation studies (DIC in AML-M3)

28. Leukemia in Children: Treatment

ALL Treatment:
Phases:
  1. Remission Induction (4-6 weeks): achieve complete remission (<5% blasts in marrow)
    • Glucocorticoid (prednisolone or dexamethasone)
    • Vincristine
    • L-Asparaginase
    • Anthracycline (daunorubicin) for high-risk
    • Target: >99% blast elimination
  2. CNS Prophylaxis (throughout): intrathecal chemotherapy (methotrexate ± cytarabine ± hydrocortisone); cranial irradiation largely replaced by IT chemotherapy
  3. Consolidation/Intensification (months): high-dose methotrexate, 6-mercaptopurine, cytarabine, cyclophosphamide (risk-adapted)
  4. Maintenance (2-3 years): oral 6-mercaptopurine daily + methotrexate weekly; pulses of vincristine + steroid
High-risk modifications:
  • Ph+ ALL: add tyrosine kinase inhibitor (imatinib/dasatinib)
  • Very high risk/relapsed: allogeneic HSCT (bone marrow transplant)
AML Treatment:
  • Intensive chemotherapy: cytarabine + anthracycline ("7+3" regimen)
  • AML-M3 (APL): ATRA (all-trans retinoic acid) + arsenic trioxide - differentiation therapy; excellent prognosis
  • Consolidation chemotherapy or HSCT
  • Gemtuzumab ozogamicin (anti-CD33 antibody-drug conjugate)
Supportive Care:
  • Tumor lysis syndrome prevention: hyperhydration, allopurinol/rasburicase
  • Infection prophylaxis: antifungals, antivirals, Pneumocystis prophylaxis (cotrimoxazole)
  • Transfusions (RBCs, platelets)
  • G-CSF (AML, post-transplant)
  • CAR-T cell therapy (tisagenlecleucel) for relapsed/refractory B-cell ALL
Prognosis: ALL - 5-year OS >90% in standard risk; AML ~60-70%

29. Acute Allergic Reactions: Urticaria & Quincke's Edema

Urticaria

  • Clinic: pruritic wheals (transient, migratory, <24h each), erythematous, raised plaques of any size; often surrounded by flare; no residual skin changes
  • Acute urticaria (<6 weeks): usually IgE-mediated; triggers - foods (nuts, shellfish, eggs, milk), drugs (penicillin, NSAIDs), infections, insect stings
  • Chronic urticaria (>6 weeks): usually idiopathic/autoimmune; rule out thyroid disease, SLE
Diagnosis: clinical; skin prick test, specific IgE if cause unclear; CBC (eosinophilia), thyroid function
Emergency care:
  • Identify and remove trigger
  • Mild-Moderate: oral antihistamine (cetirizine, loratadine, fexofenadine); non-sedating H1 blockers first-line; dosing can be up to 4x standard
  • Severe/refractory: short course oral prednisolone 20-40 mg x3-5 days
  • Chronic urticaria not responding: omalizumab (anti-IgE)

Quincke's Edema (Angioedema)

  • Deep dermal/subcutaneous tissue swelling; non-pitting, non-pruritic (often)
  • Commonly affects face (lips, eyelids, tongue), throat, hands, feet, genitalia
  • Types:
    • Allergic/histaminergic (IgE or complement-mediated): associated with urticaria; rapid onset
    • Hereditary angioedema (HAE): C1 inhibitor deficiency; no urticaria; recurrent; triggered by trauma/stress; treat with C1 inhibitor concentrate, icatibant (bradykinin B2 receptor antagonist), or tranexamic acid (acute); danazol/tranexamic acid for prophylaxis
    • ACE inhibitor-induced (bradykinin-mediated): no urticaria; treat by stopping ACE inhibitor
Emergency care:
  • Airway assessment is PRIORITY (tongue/throat angioedema = risk of asphyxia)
  • Epinephrine (adrenaline) 0.3-0.5 mg (0.01 mg/kg in children) IM into lateral thigh - FIRST-LINE for laryngeal/anaphylactic angioedema
  • Antihistamines (IV diphenhydramine)
  • IV/IM corticosteroids (hydrocortisone 200-300 mg or methylprednisolone)
  • Prepare for airway management (intubation, cricothyrotomy if needed)
  • Observe 4-6 hours minimum

30. Anaphylactic Shock

Etiology:
  • Foods: nuts (peanut, tree nuts), shellfish, fish, milk, eggs, wheat
  • Drugs: penicillin (most common drug cause), NSAIDs, muscle relaxants, IV contrast, vaccines
  • Insect stings: bee/wasp venom (Hymenoptera)
  • Latex, blood products, exercise-induced (rare), idiopathic
Pathophysiology: IgE crosslinking by allergen -> mast cell/basophil degranulation -> massive histamine, tryptase, prostaglandins, leukotrienes release -> vasodilation, increased vascular permeability, bronchospasm, smooth muscle contraction
Clinical Manifestations (multi-system, rapid onset within minutes):
  • Cutaneous (90%): urticaria, angioedema, flushing, pruritus
  • Respiratory (70%): bronchospasm (wheeze), upper airway edema (stridor, hoarseness, dyspnea)
  • Cardiovascular (45%): hypotension, tachycardia, arrhythmia, cardiovascular collapse/shock
  • GI (30-45%): nausea, vomiting, diarrhea, crampy abdominal pain
  • Neurological: dizziness, syncope, confusion, anxiety (sense of doom)
WAO/EAACI Diagnostic criteria: Anaphylaxis is likely when one of three criteria met:
  1. Acute onset + skin/mucosal symptoms + either respiratory compromise OR hypotension
  2. Acute onset + two or more systems involved after allergen exposure
  3. Hypotension alone after known allergen exposure
Emergency Care (sequence):
  1. STOP trigger (stop infusion, remove stinger)
  2. Epinephrine 0.3-0.5 mg (1:1000) IM - LATERAL THIGH (children: 0.01 mg/kg, max 0.5 mg); repeat every 5-15 min if needed - THIS IS THE CORNERSTONE OF TREATMENT
  3. Position: supine with legs elevated (or recovery position if vomiting; upright if respiratory distress); do NOT stand them up
  4. Call for help/ambulance; oxygen (high-flow 10-15 L/min)
  5. IV access: IV normal saline 1-2 L bolus (adults); 10-20 mL/kg (children) for hypotension
  6. Second-line (NEVER replace epinephrine):
    • H1 antihistamine: IV diphenhydramine or chlorphenamine (for urticaria/itch; does NOT treat shock or bronchospasm)
    • H2 antihistamine: ranitidine/famotidine IV
    • Glucocorticoids: hydrocortisone 200-300 mg IV or methylprednisolone (prevent/attenuate biphasic reaction; NOT for acute shock)
    • Salbutamol nebulization (for persistent bronchospasm)
    • Glucagon IV (for patients on beta-blockers - refractory to epinephrine)
  7. Vasopressors (dopamine, norepinephrine) if refractory hypotension despite fluids + epinephrine
  8. Airway management: intubation/surgical airway if laryngeal edema
Observation:
  • Minimum 4-6h observation after reaction resolves (biphasic risk up to 72h)
  • Discharge with 2 auto-injector epinephrine pens (EpiPen); anaphylaxis action plan
  • Refer to allergist for identification of trigger and desensitization
Prognosis:
  • Good if epinephrine given promptly
  • Mortality <1% with rapid treatment; higher risk if: delayed epinephrine, severe initial reaction, asthma, cardiovascular disease, beta-blocker use
  • Biphasic reaction in 5-20% of cases (second wave 1-72h later)

This review covers all 30 Section 3 topics. Each answer is structured for exam use: etiology/pathogenesis first, then clinical features, diagnosis, and treatment. Focus on bold-highlighted key points for highest-yield recall.

Can you make pdf for this

Reading File
Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "workspace ready"

Writing File

~/section3_pediatrics.py

from reportlab.lib.pagesizes import A4
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm
from reportlab.lib import colors
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
    HRFlowable, PageBreak, KeepTogether
)
from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY

OUTPUT = "/tmp/workspace/Section3_Pediatrics_ExamReview.pdf"

doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    rightMargin=2*cm,
    leftMargin=2*cm,
    topMargin=2.2*cm,
    bottomMargin=2*cm,
    title="Section 3 – Pediatrics Exam Review",
    author="Orris Medical Assistant"
)

styles = getSampleStyleSheet()

# Custom styles
title_style = ParagraphStyle(
    'CustomTitle',
    parent=styles['Title'],
    fontSize=20,
    textColor=colors.HexColor('#1a3a5c'),
    spaceAfter=6,
    spaceBefore=0,
    alignment=TA_CENTER,
    fontName='Helvetica-Bold',
)
subtitle_style = ParagraphStyle(
    'Subtitle',
    parent=styles['Normal'],
    fontSize=11,
    textColor=colors.HexColor('#4a6fa5'),
    spaceAfter=16,
    alignment=TA_CENTER,
    fontName='Helvetica',
)
h1_style = ParagraphStyle(
    'H1',
    parent=styles['Normal'],
    fontSize=13,
    textColor=colors.white,
    backColor=colors.HexColor('#1a3a5c'),
    spaceBefore=14,
    spaceAfter=6,
    leftIndent=-0.3*cm,
    rightIndent=-0.3*cm,
    leading=18,
    fontName='Helvetica-Bold',
    borderPadding=(4, 8, 4, 8),
)
h2_style = ParagraphStyle(
    'H2',
    parent=styles['Normal'],
    fontSize=11,
    textColor=colors.HexColor('#1a3a5c'),
    spaceBefore=8,
    spaceAfter=3,
    fontName='Helvetica-Bold',
    borderPadding=(2, 0, 2, 0),
)
body_style = ParagraphStyle(
    'Body',
    parent=styles['Normal'],
    fontSize=9.5,
    textColor=colors.HexColor('#222222'),
    spaceAfter=3,
    spaceBefore=1,
    leading=14,
    fontName='Helvetica',
    alignment=TA_JUSTIFY,
)
bullet_style = ParagraphStyle(
    'Bullet',
    parent=styles['Normal'],
    fontSize=9.5,
    textColor=colors.HexColor('#222222'),
    spaceAfter=2,
    spaceBefore=1,
    leading=13,
    fontName='Helvetica',
    leftIndent=14,
    bulletIndent=4,
)
bullet2_style = ParagraphStyle(
    'Bullet2',
    parent=styles['Normal'],
    fontSize=9,
    textColor=colors.HexColor('#333333'),
    spaceAfter=1,
    spaceBefore=0,
    leading=12,
    fontName='Helvetica',
    leftIndent=28,
    bulletIndent=18,
)
note_style = ParagraphStyle(
    'Note',
    parent=styles['Normal'],
    fontSize=8.5,
    textColor=colors.HexColor('#555555'),
    spaceAfter=4,
    spaceBefore=2,
    leading=12,
    fontName='Helvetica-Oblique',
    leftIndent=14,
)

def h1(text):
    return Paragraph(f"&nbsp;&nbsp;{text}", h1_style)

def h2(text):
    return Paragraph(text, h2_style)

def p(text):
    return Paragraph(text, body_style)

def b(text):
    return Paragraph(f"• {text}", bullet_style)

def b2(text):
    return Paragraph(f"- {text}", bullet2_style)

def note(text):
    return Paragraph(text, note_style)

def sp(h=4):
    return Spacer(1, h)

def hr():
    return HRFlowable(width="100%", thickness=0.5, color=colors.HexColor('#cccccc'), spaceAfter=4, spaceBefore=4)

def make_table(headers, rows, col_widths=None):
    data = [headers] + rows
    if col_widths is None:
        n = len(headers)
        w = (A4[0] - 4*cm) / n
        col_widths = [w]*n
    tbl = Table(data, colWidths=col_widths, repeatRows=1)
    tbl.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a3a5c')),
        ('TEXTCOLOR', (0,0), (-1,0), colors.white),
        ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
        ('FONTSIZE', (0,0), (-1,0), 8.5),
        ('FONTNAME', (0,1), (-1,-1), 'Helvetica'),
        ('FONTSIZE', (0,1), (-1,-1), 8),
        ('BACKGROUND', (0,1), (-1,-1), colors.HexColor('#f5f8fc')),
        ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#f5f8fc'), colors.white]),
        ('GRID', (0,0), (-1,-1), 0.4, colors.HexColor('#b0c4de')),
        ('ALIGN', (0,0), (-1,-1), 'LEFT'),
        ('VALIGN', (0,0), (-1,-1), 'TOP'),
        ('TOPPADDING', (0,0), (-1,-1), 3),
        ('BOTTOMPADDING', (0,0), (-1,-1), 3),
        ('LEFTPADDING', (0,0), (-1,-1), 5),
        ('RIGHTPADDING', (0,0), (-1,-1), 5),
        ('WORDWRAP', (0,0), (-1,-1), True),
    ]))
    return tbl

story = []

# ── TITLE PAGE ────────────────────────────────────────────────────────────────
story.append(Spacer(1, 1.5*cm))
story.append(Paragraph("Section 3", title_style))
story.append(Paragraph("Pediatrics Exam Review", title_style))
story.append(Spacer(1, 0.3*cm))
story.append(Paragraph("30 High-Yield Topics | Exam-Oriented Answers", subtitle_style))
story.append(HRFlowable(width="60%", thickness=2, color=colors.HexColor('#4a6fa5'), spaceAfter=20))
story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# Q1
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("1. Pneumonia: Classification & Diagnosis"))
story.append(sp())
story.append(h2("Classification"))
story.append(b("<b>By etiology:</b> bacterial (S. pneumoniae most common), viral, mycoplasma, fungal, aspiration"))
story.append(b("<b>By extent:</b> lobar (segmental), bronchopneumonia (lobular), interstitial"))
story.append(b("<b>By acquisition:</b> community-acquired (CAP), hospital-acquired (HAP, >48h), ventilator-associated (VAP)"))
story.append(b("<b>Age-based etiology:</b>"))
story.append(b2("Neonates: GBS, E. coli, Klebsiella"))
story.append(b2("1–3 months: Chlamydia, RSV"))
story.append(b2("3 months–5 years: S. pneumoniae, RSV, Hib"))
story.append(b2(">5 years: S. pneumoniae, Mycoplasma, Chlamydophila"))
story.append(sp())
story.append(h2("Diagnostic Criteria"))
story.append(b("<b>Symptoms:</b> fever, cough, tachypnea (key sign), dyspnea, chest pain"))
story.append(b("<b>Signs:</b> dullness to percussion, bronchial breath sounds, crepitations"))
story.append(b("<b>WHO Tachypnea thresholds:</b>"))
story.append(make_table(
    [Paragraph('<b>Age</b>', body_style), Paragraph('<b>RR (tachypnea)</b>', body_style)],
    [['<2 months', '>60/min'], ['2–12 months', '>50/min'], ['1–5 years', '>40/min'], ['>5 years', '>30/min']],
    col_widths=[8*cm, 8*cm]
))
story.append(sp(6))
story.append(b("<b>CXR:</b> alveolar infiltrates, air bronchograms, interstitial pattern"))
story.append(b("<b>Labs:</b> CBC (leukocytosis in bacterial, lymphocytosis in viral), CRP, ESR, procalcitonin, blood culture, sputum culture"))
story.append(b("<b>CURB-65 (adults):</b> Confusion, Urea >7, RR >30, BP <90/60, age >65 — score 0–1 outpatient; ≥3 ICU"))

# ══════════════════════════════════════════════════════════════════════════════
# Q2
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("2. Pneumonia: Complications. Pleurisy & ARDS"))
story.append(sp())
story.append(h2("Complications"))
story.append(b("Parapneumonic effusion / empyema (most common)"))
story.append(b("Lung abscess (cavitation on CXR)"))
story.append(b("Pneumothorax / pyopneumothorax"))
story.append(b("Sepsis, bacteremia"))
story.append(b("ARDS, respiratory failure"))
story.append(b("Pericarditis, meningitis (hematogenous spread)"))
story.append(sp())
story.append(h2("Pleurisy — Clinic"))
story.append(b("Pleuritic chest pain: sharp, worsens with inspiration/cough, relieved by splinting"))
story.append(b("Pleural friction rub (dry pleurisy)"))
story.append(b("Fever, dyspnea; with effusion: dullness, decreased breath sounds, tracheal deviation"))
story.append(b("Diagnosis: CXR (>200 mL blunts costophrenic angle), USS, thoracocentesis (Light's criteria)"))
story.append(sp())
story.append(h2("ARDS — Berlin Definition & Clinic"))
story.append(make_table(
    [Paragraph('<b>Severity</b>', body_style), Paragraph('<b>PaO2/FiO2</b>', body_style)],
    [['Mild', '200–300 mmHg'], ['Moderate', '100–200 mmHg'], ['Severe', '<100 mmHg']],
    col_widths=[8*cm, 8*cm]
))
story.append(sp(6))
story.append(b("Clinic: refractory hypoxemia, tachypnea, bilateral crepitations, cyanosis, accessory muscle use"))
story.append(b("Pathophysiology: diffuse alveolar damage → non-cardiogenic pulmonary edema"))
story.append(b("Management: lung-protective ventilation (TV 6 mL/kg, PEEP, prone positioning), treat underlying cause"))

# ══════════════════════════════════════════════════════════════════════════════
# Q3
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("3. Pneumonia: Treatment"))
story.append(sp())
story.append(h2("Empirical Antibiotics — CAP"))
story.append(make_table(
    [Paragraph('<b>Setting</b>', body_style), Paragraph('<b>Regimen</b>', body_style)],
    [
        ['Outpatient, no comorbidities', 'Amoxicillin 500 mg TID ×5–7d OR Azithromycin'],
        ['Outpatient with comorbidities', 'Amox-clav + macrolide OR respiratory fluoroquinolone'],
        ['Inpatient (non-ICU)', 'Beta-lactam + macrolide OR respiratory FQ'],
        ['ICU/severe', 'Beta-lactam + macrolide ± vancomycin/linezolid (MRSA risk)'],
        ['Children <5y', 'Amoxicillin first-line; Azithromycin if atypical suspected'],
        ['Children (hospitalized)', 'IV ampicillin or cefuroxime'],
    ],
    col_widths=[6.5*cm, 10.5*cm]
))
story.append(sp(6))
story.append(h2("Supportive Care"))
story.append(b("Antipyretics (paracetamol/ibuprofen), adequate hydration"))
story.append(b("Oxygen — maintain SpO2 >94%"))
story.append(b("Chest physiotherapy, bronchodilators if bronchospasm"))
story.append(b("<b>Duration:</b> 5–7 days uncomplicated; 14–21 days Staph/Klebsiella; 14 days atypicals"))

# ══════════════════════════════════════════════════════════════════════════════
# Q4
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("4. Bronchial Asthma: Clinic & Controlled Asthma"))
story.append(sp())
story.append(h2("Clinical Features"))
story.append(b("Recurrent episodes: wheeze, cough (worse at night/early morning), breathlessness, chest tightness"))
story.append(b("Triggers: allergens, exercise, viral URTI, cold air, smoke, stress"))
story.append(b("Physical: expiratory wheeze, prolonged expiration, hyperinflation, barrel chest (chronic)"))
story.append(b("Atopic history: eczema, allergic rhinitis, family history"))
story.append(sp())
story.append(h2("'Controlled Asthma' — GINA Criteria (past 4 weeks ALL present)"))
story.append(b("Daytime symptoms ≤2 times/week"))
story.append(b("No nighttime waking due to asthma"))
story.append(b("Reliever use ≤2 times/week"))
story.append(b("No activity limitation"))
story.append(b("FEV1/PEF ≥80% predicted"))
story.append(note("Partly controlled: 1–2 features present | Uncontrolled: 3–4 features present"))
story.append(note("Control level guides step-up/step-down of therapy (GINA step approach)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q5
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("5. Bronchial Asthma: Diagnosis & Severity Assessment"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("<b>Spirometry (>6 years):</b> FEV1/FVC <0.8; reversibility = FEV1 ↑≥12% and ≥200 mL after salbutamol"))
story.append(b("<b>Peak flow monitoring:</b> diurnal variability >20%"))
story.append(b("<b>Bronchial provocation test:</b> methacholine/exercise if spirometry normal"))
story.append(b("<b>Allergy tests:</b> skin prick test, specific IgE (RAST)"))
story.append(b("<b>FeNO:</b> >25 ppb = eosinophilic airway inflammation"))
story.append(sp())
story.append(h2("Disease Severity"))
story.append(make_table(
    ['', Paragraph('<b>Intermittent</b>', body_style), Paragraph('<b>Mild Persistent</b>', body_style), Paragraph('<b>Moderate</b>', body_style), Paragraph('<b>Severe</b>', body_style)],
    [
        ['Daytime', '<1×/week', '>1×/wk, <daily', 'Daily', 'Continuous'],
        ['Nighttime', '≤2×/month', '>2×/month', '>1×/week', 'Frequent'],
        ['FEV1/PEF', '>80%', '>80%', '60–80%', '<60%'],
        ['Variability', '<20%', '20–30%', '>30%', '>30%'],
    ],
    col_widths=[3.5*cm, 3.5*cm, 3.8*cm, 3.2*cm, 3*cm]
))
story.append(sp(6))
story.append(h2("Attack Severity"))
story.append(make_table(
    ['Parameter', 'Mild', 'Moderate', 'Severe', 'Life-threatening'],
    [
        ['Breathlessness', 'Walking', 'Talking', 'At rest', '—'],
        ['Speech', 'Sentences', 'Phrases', 'Words', 'Silent chest'],
        ['RR', 'Increased', 'Increased', '>30/min', 'Irregular'],
        ['HR', '<100', '100–120', '>120', 'Bradycardia'],
        ['SaO2', '>95%', '91–95%', '<91%', '<90%'],
        ['PEF', '>70%', '50–70%', '<50%', '<33%'],
    ],
    col_widths=[3.5*cm, 3*cm, 3*cm, 3*cm, 3.5*cm]
))

# ══════════════════════════════════════════════════════════════════════════════
# Q6
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("6. Bronchial Asthma: Treatment & Emergency Care"))
story.append(sp())
story.append(h2("Step Therapy (GINA)"))
story.append(make_table(
    [Paragraph('<b>Step</b>', body_style), Paragraph('<b>Severity</b>', body_style), Paragraph('<b>Treatment</b>', body_style)],
    [
        ['Step 1', 'Intermittent', 'SABA (salbutamol) PRN only'],
        ['Step 2', 'Mild persistent', 'Low-dose ICS + SABA PRN'],
        ['Step 3', 'Moderate', 'Low-dose ICS/LABA OR medium-dose ICS'],
        ['Step 4', 'Severe', 'Medium/high-dose ICS/LABA'],
        ['Step 5', 'Add-on', 'Tiotropium, anti-IgE (omalizumab), oral corticosteroids'],
    ],
    col_widths=[2.5*cm, 4*cm, 10.5*cm]
))
story.append(sp(6))
story.append(h2("Acute Attack Management"))
story.append(b("<b>Mild–Moderate:</b> Salbutamol 2.5–5 mg nebulized q20 min ×3 → oral prednisolone 1–2 mg/kg/day × 3–5d → O2 (SpO2 >94%) → add ipratropium bromide"))
story.append(b("<b>Severe/Emergency:</b>"))
story.append(b2("High-flow oxygen"))
story.append(b2("Salbutamol + ipratropium continuous nebulization"))
story.append(b2("IV/oral systemic corticosteroids (prednisolone 2 mg/kg or methylprednisolone)"))
story.append(b2("<b>IV magnesium sulfate</b> 25–75 mg/kg (max 2.5 g) over 20 min"))
story.append(b2("IV aminophylline if no response (5 mg/kg loading)"))
story.append(b2("Heliox, NIV, intubation in extremis"))

# ══════════════════════════════════════════════════════════════════════════════
# Q7
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("7. Acute Rheumatic Fever: Classification, Clinic, Diagnosis"))
story.append(sp())
story.append(p("Inflammatory disease following Group A Streptococcal (GAS) pharyngitis, 2–4 weeks later."))
story.append(sp())
story.append(h2("Jones Criteria 2015 — Diagnosis"))
story.append(p("<b>Prerequisite:</b> Evidence of preceding GAS infection PLUS 2 major criteria OR 1 major + 2 minor criteria"))
story.append(sp(4))
story.append(h2("Major Criteria (JONES)"))
story.append(b("<b>J</b> — Joint (migratory polyarthritis) — most common (75%)"))
story.append(b("<b>O</b> — (c)Horea (Sydenham's) — involuntary movements"))
story.append(b("<b>N</b> — Nodules (subcutaneous) — over bony prominences"))
story.append(b("<b>E</b> — Erythema marginatum — skin rash"))
story.append(b("<b>S</b> — carditis (Sydenham) — pancarditis; most serious manifestation"))
story.append(sp())
story.append(h2("Minor Criteria"))
story.append(b("Fever >38.5°C, elevated ESR/CRP, prolonged PR interval on ECG, arthralgia"))
story.append(sp())
story.append(h2("GAS Evidence"))
story.append(b("Positive throat culture or rapid antigen test"))
story.append(b("Elevated/rising ASO titer (>200 Todd units in children), Anti-DNase B elevated"))
story.append(sp())
story.append(h2("Carditis Clinic"))
story.append(b("Tachycardia out of proportion to fever, pericardial friction rub"))
story.append(b("New murmur: mitral regurgitation (apical blowing systolic), aortic regurgitation (early diastolic)"))
story.append(b("CCF signs; Echo: valve regurgitation, pericardial effusion"))

# ══════════════════════════════════════════════════════════════════════════════
# Q8
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("8. Acute Rheumatic Fever: Treatment & Prevention"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>GAS Eradication:</b> Benzathine penicillin G IM single dose (600,000 U if <30 kg; 1.2 MU if >30 kg) OR oral amoxicillin ×10d"))
story.append(b("<b>Anti-inflammatory:</b>"))
story.append(b2("Arthritis only: Aspirin 80–100 mg/kg/day ×4–8 weeks"))
story.append(b2("Carditis: Prednisolone 2 mg/kg/day ×2–4 weeks then taper → followed by aspirin"))
story.append(b("<b>Chorea:</b> Haloperidol or valproate; steroids may help; self-limiting"))
story.append(b("<b>CCF:</b> Diuretics, ACE inhibitors, digoxin"))
story.append(sp())
story.append(h2("Secondary Prevention (Penicillin Prophylaxis)"))
story.append(b("Benzathine penicillin G 1.2 MU IM every 3–4 weeks"))
story.append(make_table(
    [Paragraph('<b>Category</b>', body_style), Paragraph('<b>Duration</b>', body_style)],
    [
        ['ARF without carditis', '5 years or until age 21 (whichever longer)'],
        ['ARF with carditis, no residual valve disease', '10 years or until age 21'],
        ['ARF with persistent valve disease', '10 years or age 40 (lifelong if high risk)'],
    ],
    col_widths=[8*cm, 9*cm]
))
story.append(sp(6))
story.append(b("<b>Primary prevention:</b> Treat GAS pharyngitis within 9 days with penicillin"))

# ══════════════════════════════════════════════════════════════════════════════
# Q9
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("9. Juvenile Rheumatoid Arthritis (JIA)"))
story.append(sp())
story.append(h2("Definition & Etiology"))
story.append(p("Chronic arthritis in children <16 years, lasting >6 weeks, after excluding other causes. Multifactorial: genetic (HLA) + environmental triggers; autoimmune pathogenesis (TNF-α, IL-1, IL-6)."))
story.append(sp())
story.append(h2("ILAR Classification (Subtypes)"))
story.append(make_table(
    [Paragraph('<b>Subtype</b>', body_style), Paragraph('<b>Key Features</b>', body_style)],
    [
        ['Oligoarticular', '<5 joints, girls, ANA+, risk of uveitis (most common)'],
        ['Polyarticular RF−', '>5 joints, any age'],
        ['Polyarticular RF+', 'Like adult RA, erosive'],
        ['Systemic (Still\'s)', 'Quotidian fever, salmon rash, hepatosplenomegaly, serositis'],
        ['Enthesitis-related', 'Boys, HLA-B27, sacroiliac involvement'],
        ['Psoriatic', 'Psoriasis + arthritis'],
    ],
    col_widths=[5*cm, 12*cm]
))
story.append(sp(6))
story.append(h2("Clinic"))
story.append(b("Joint swelling, warmth, pain, morning stiffness >1 hour"))
story.append(b("Systemic JIA: high spiking fever, evanescent rash, lymphadenopathy, hepatosplenomegaly, pericarditis"))
story.append(b("Uveitis (oligoarticular ANA+) — often asymptomatic, requires slit-lamp screening"))
story.append(b("Growth retardation, micrognathia (TMJ involvement)"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("Clinical (>6 weeks, <16 years, exclusion); CBC, ESR, CRP, ANA, RF, HLA-B27, ferritin (very high in systemic)"))
story.append(b("X-ray: osteoporosis, joint space narrowing, erosions (late); USS/MRI: synovitis, effusion"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>NSAIDs:</b> naproxen, ibuprofen (symptom relief)"))
story.append(b("<b>Intra-articular corticosteroids:</b> triamcinolone (oligoarticular)"))
story.append(b("<b>DMARDs:</b> Methotrexate (first-line DMARD), sulfasalazine (enthesitis)"))
story.append(b("<b>Biologics:</b> Anti-TNF (etanercept, adalimumab); IL-1 inhibitor (canakinumab — systemic JIA); IL-6 inhibitor (tocilizumab); Abatacept"))
story.append(b("Physiotherapy, occupational therapy, regular ophthalmology monitoring"))

# ══════════════════════════════════════════════════════════════════════════════
# Q10
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("10. GP Tactics in Diagnosis of Congenital Heart Defects"))
story.append(sp())
story.append(h2("When to Suspect CHD"))
story.append(b("Cyanosis (unresponsive to O2 — nitrogen washout test)"))
story.append(b("Heart murmur, tachycardia, tachypnea, poor feeding, failure to thrive"))
story.append(b("Hepatomegaly, sweating during feeds (CCF signs)"))
story.append(b("Absent femoral pulses = coarctation; differential cyanosis (PDA with R-L shunt)"))
story.append(sp())
story.append(h2("GP Steps"))
story.append(b("<b>History:</b> family history, prenatal infections (rubella), drug exposure, chromosomal anomalies"))
story.append(b2("Down syndrome → AVSD, VSD; Turner → bicuspid aortic valve, coarctation"))
story.append(b("<b>Exam:</b> inspect (cyanosis, clubbing, dysmorphia), palpate (thrills/heaves), auscultate (murmurs)"))
story.append(b("<b>4-limb BP</b> (coarctation: arm BP > leg BP)"))
story.append(b("<b>Pulse oximetry</b> pre- and post-ductal (right hand + foot)"))
story.append(b("<b>ECG, CXR</b> (heart size, pulmonary vascularity)"))
story.append(b("<b>Urgent referral to pediatric cardiologist + echocardiography</b> (definitive)"))
story.append(b("<b>Newborn pulse oximetry screening</b> at 24–48h (universal recommendation)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q11
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("11. CHD — Enrichment of Pulmonary Circulation: PDA & Truncus Arteriosus"))
story.append(sp())
story.append(h2("Patent Ductus Arteriosus (PDA)"))
story.append(b("Failure of ductus arteriosus to close after birth (normally by 48–72h)"))
story.append(b("<b>Clinic:</b> continuous 'machinery' murmur (Gibson), left infraclav; wide pulse pressure; bounding pulses; tachycardia; CCF if large"))
story.append(b("<b>CXR:</b> cardiomegaly, increased pulmonary vascular markings"))
story.append(b("<b>Echo:</b> left-to-right shunt"))
story.append(b("<b>Eisenmenger:</b> uncorrected → R-L shunt → differential cyanosis (lower limbs blue, upper pink)"))
story.append(b("<b>Treatment:</b> Indomethacin/ibuprofen (premature); surgical ligation or catheter-based device closure"))
story.append(sp())
story.append(h2("Common Arterial Trunk (Truncus Arteriosus)"))
story.append(b("Single arterial trunk from both ventricles + VSD always present"))
story.append(b("<b>Clinic:</b> early cyanosis, CCF (weeks 1–2), bounding pulses, single loud S2"))
story.append(b("<b>Treatment:</b> Rastelli procedure (patch VSD + RV-to-PA conduit) in early infancy"))

# ══════════════════════════════════════════════════════════════════════════════
# Q12
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("12. CHD — Decreased Pulmonary Blood Flow: PS & Tetralogy of Fallot"))
story.append(sp())
story.append(h2("Isolated Pulmonary Artery Stenosis"))
story.append(b("Obstruction to RV outflow (valvular most common)"))
story.append(b("<b>Mild:</b> asymptomatic; ejection click + systolic murmur at upper LSB, radiating to back"))
story.append(b("<b>Severe:</b> dyspnea, fatigue, RVF, cyanosis (via foramen ovale)"))
story.append(b("<b>CXR:</b> post-stenotic PA dilation; oligemic fields (severe) | <b>ECG:</b> RVH"))
story.append(b("<b>Treatment:</b> Mild (gradient <40 mmHg): observe; Moderate-severe: balloon valvuloplasty"))
story.append(sp())
story.append(h2("Tetralogy of Fallot (TOF) — Most Common Cyanotic CHD"))
story.append(b("<b>Four components (PROVE):</b> Pulmonary stenosis, Right ventricular hypertrophy, Overriding aorta, Ventricular septal defect"))
story.append(b("<b>Clinic:</b> cyanosis, 'Tet spells' (hypercyanotic episodes), squatting posture, clubbing"))
story.append(b("<b>Tet spell triggers:</b> feeding, crying, defecation (infundibular spasm)"))
story.append(b("<b>CXR:</b> 'Boot-shaped heart' (coeur en sabot), concave PA segment, oligemic lungs"))
story.append(sp())
story.append(h2("Management of Tet Spell"))
story.append(b("Knee-chest/squatting position → O2 → IV morphine → IV fluids → phenylephrine IV → NaHCO3"))
story.append(b("Propranolol (relaxes infundibular spasm)"))
story.append(b("<b>Definitive:</b> Surgical total correction OR palliative Blalock-Taussig shunt"))

# ══════════════════════════════════════════════════════════════════════════════
# Q13
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("13. Syndrome of Vegetative Dystonia"))
story.append(sp())
story.append(h2("Classification"))
story.append(b("<b>By tone:</b> sympathicotonic, vagotonic, mixed"))
story.append(b("<b>By course:</b> permanent, paroxysmal (crises), mixed"))
story.append(b("<b>By origin:</b> primary (constitutional), secondary (somatic, neurosis, endocrine)"))
story.append(sp())
story.append(h2("Clinic"))
story.append(b("<b>Cardiovascular:</b> palpitations, labile BP, chest pain, orthostatic changes"))
story.append(b("<b>Respiratory:</b> 'unsatisfied deep breath,' hyperventilation"))
story.append(b("<b>GI:</b> nausea, abdominal pain, diarrhea/constipation"))
story.append(b("<b>Skin:</b> dermographism, cold/sweaty extremities, pallor/flushing"))
story.append(b("<b>Neurological:</b> headaches, dizziness, fainting, sleep disturbances, anxiety, fatigue"))
story.append(sp())
story.append(h2("Autonomic Crises"))
story.append(b("<b>Sympathoadrenal (panic-attack-like):</b> anxiety, tachycardia, hypertension, pallor, tremor"))
story.append(b("<b>Vagoinsular:</b> bradycardia, hypotension, nausea, profuse sweating"))
story.append(sp())
story.append(h2("Diagnosis & Treatment"))
story.append(b("Clinical exclusion of organic disease; Kerdo index, orthostatic test, ECG"))
story.append(b("Lifestyle: regular sleep, exercise, stress reduction; psychotherapy"))
story.append(b("<b>Sympathicotonic:</b> beta-blockers (propranolol), benzodiazepines"))
story.append(b("<b>Vagotonic:</b> anticholinergics, adaptogens (ginseng)"))
story.append(b("<b>Severe:</b> SSRIs, anxiolytics"))

# ══════════════════════════════════════════════════════════════════════════════
# Q14
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("14. Chronic Gastritis"))
story.append(sp())
story.append(h2("Etiology & Pathogenesis"))
story.append(make_table(
    [Paragraph('<b>Type</b>', body_style), Paragraph('<b>Cause</b>', body_style), Paragraph('<b>Location</b>', body_style)],
    [
        ['Type B', 'H. pylori (most common)', 'Antrum'],
        ['Type A', 'Autoimmune (anti-parietal cell Ab)', 'Body/Fundus'],
        ['Type C', 'NSAIDs, bile reflux, alcohol', 'Antrum/diffuse'],
    ],
    col_widths=[3*cm, 8.5*cm, 5.5*cm]
))
story.append(sp(6))
story.append(h2("Clinic & Diagnosis"))
story.append(b("Often asymptomatic; epigastric pain/discomfort, nausea, belching, bloating"))
story.append(b("Autoimmune: B12 deficiency (megaloblastic anemia, neuropathy, glossitis)"))
story.append(b("<b>Diagnosis:</b> Endoscopy + biopsy (gold standard); H. pylori: urea breath test, stool antigen, CLO test"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>H. pylori:</b> Triple therapy: PPI + amoxicillin + clarithromycin ×14 days; confirm eradication with UBT 4 weeks later"))
story.append(b("<b>Bismuth quadruple (2nd line):</b> PPI + bismuth + metronidazole + tetracycline ×14 days"))
story.append(b("<b>Autoimmune:</b> B12 IM replacement; PPI"))
story.append(b("<b>General:</b> PPI (omeprazole 20–40 mg), H2 blockers, avoid NSAIDs/alcohol"))

# ══════════════════════════════════════════════════════════════════════════════
# Q15
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("15. Peptic Ulcer Disease (PUD)"))
story.append(sp())
story.append(h2("Etiology & Pathogenesis"))
story.append(b("<b>Etiology:</b> H. pylori (80–90% DU; 60–70% GU), NSAIDs, Zollinger-Ellison syndrome, stress ulcers"))
story.append(b("<b>Pathogenesis:</b> Imbalance: aggressive (acid, pepsin, H. pylori, NSAIDs) vs defensive (mucus, bicarb, PGs, mucosal blood flow)"))
story.append(sp())
story.append(h2("Classification & Clinic"))
story.append(b("<b>Duodenal ulcer:</b> epigastric pain 2–4h after meals (hunger pain), relieved by food, nocturnal pain"))
story.append(b("<b>Gastric ulcer:</b> epigastric pain during/after meals, weight loss"))
story.append(b("<b>Forrest classification (bleeding risk):</b> Ia/b = active bleeding; IIa/b/c = stigmata; III = clean base"))
story.append(sp())
story.append(h2("Complications"))
story.append(b("Bleeding, perforation, penetration, pyloric stenosis, malignant transformation (GU only)"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>H. pylori eradication</b> (triple/quadruple therapy — see Q14)"))
story.append(b("<b>Acid suppression:</b> PPI ×4 weeks (DU) or ×8 weeks (GU)"))
story.append(b("<b>Stop NSAIDs;</b> sucralfate (mucosal protective)"))
story.append(b("<b>Bleeding:</b> Endoscopic hemostasis + IV PPI infusion (80 mg bolus → 8 mg/h); surgery if endoscopy fails"))
story.append(b("<b>Perforation:</b> Emergency surgery (omental patch)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q16
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("16. Biliary Dyskinesia"))
story.append(sp())
story.append(h2("Definition & Types"))
story.append(b("Disordered gallbladder/sphincter of Oddi motility without organic pathology"))
story.append(b("<b>Hypermotile (hyperkinetic):</b> excessive contraction; sharp crampy pain after eating; thin/nervous patients"))
story.append(b("<b>Hypomotile (hypokinetic):</b> poor emptying (EF <40%); dull aching; overweight patients"))
story.append(sp())
story.append(h2("Clinic"))
story.append(b("RUQ/epigastric colicky pain after fatty foods, nausea, vomiting, belching"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("<b>USS:</b> gallbladder size/wall, exclude stones; dynamic USS with CCK stimulation"))
story.append(b("<b>HIDA scan:</b> EF <40% = hypokinetic"))
story.append(b("<b>Sphincter of Oddi manometry</b> if SOD suspected"))
story.append(b("Exclude organic disease: LFTs, lipase, CBC"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>General:</b> small frequent meals, low fat, regular eating, stress reduction"))
story.append(b("<b>Hypomotile:</b> prokinetics (domperidone), ursodeoxycholic acid"))
story.append(b("<b>Hypermotile:</b> antispasmodics (drotaverine/No-spa, mebeverine, hyoscine), magnesium"))
story.append(b("<b>Refractory hypokinesia:</b> cholecystectomy"))

# ══════════════════════════════════════════════════════════════════════════════
# Q17
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("17. Acute Post-Streptococcal Glomerulonephritis: Etiology, Pathogenesis, Classification"))
story.append(sp())
story.append(h2("Etiology"))
story.append(b("Group A beta-hemolytic Streptococcus (nephritogenic strains)"))
story.append(b("M types 1, 3, 12 (pharyngitis); types 47, 49, 57 (skin/impetigo)"))
story.append(b("Latent period: 1–3 weeks after pharyngitis; 3–6 weeks after impetigo"))
story.append(sp())
story.append(h2("Pathogenesis"))
story.append(b("Streptococcal antigens (NAPlr, SPEB) deposit in glomeruli"))
story.append(b("Type III hypersensitivity: immune complex → complement activation (C3 deposition) → glomerular inflammation"))
story.append(b("IF: 'Lumpy-bumpy' subepithelial IgG + C3 deposits"))
story.append(sp())
story.append(h2("Classification"))
story.append(b("<b>By clinical syndrome:</b> nephritic, nephrotic, asymptomatic urinary abnormalities, RPGN (rare)"))
story.append(b("<b>By severity:</b> mild, moderate, severe"))
story.append(b("<b>By course:</b> acute, subacute, rapidly progressive"))

# ══════════════════════════════════════════════════════════════════════════════
# Q18
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("18. APSGN: Differential Diagnosis & Treatment"))
story.append(sp())
story.append(h2("Differential Diagnosis"))
story.append(make_table(
    [Paragraph('<b>Disease</b>', body_style), Paragraph('<b>Distinguishing Features</b>', body_style)],
    [
        ['IgA nephropathy', 'Hematuria during (not after) URTI; normal complement'],
        ['Lupus nephritis', 'Young females; ANA+; low C3 AND C4'],
        ['MPGN', 'Low C3 persists >8 weeks'],
        ['Alport syndrome', 'Hereditary; deafness; X-linked'],
        ['RPGN', 'Goodpasture (anti-GBM); ANCA vasculitis'],
        ['Minimal change disease', 'Nephrotic; steroid-responsive; normal complement'],
    ],
    col_widths=[5*cm, 12*cm]
))
story.append(sp(6))
story.append(h2("Key APSGN Features"))
story.append(b("Preceding GAS infection; elevated ASO/anti-DNase B; low C3 (normalizes by 6–8 weeks); C4 usually normal"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("Hospitalization; fluid + sodium restriction"))
story.append(b("<b>Antihypertensives:</b> calcium channel blockers, hydralazine; diuretics: furosemide"))
story.append(b("<b>Antibiotics:</b> penicillin/amoxicillin ×10d (eradicate GAS; does NOT alter GN course)"))
story.append(b("<b>Dialysis</b> if: severe AKI, hyperkalemia, acidosis, refractory fluid overload"))

# ══════════════════════════════════════════════════════════════════════════════
# Q19
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("19. APSGN with Nephritic Syndrome: Clinic & Treatment"))
story.append(sp())
story.append(h2("Classic Nephritic Triad"))
story.append(b("<b>1. Hematuria</b> — macroscopic ('cola/smoky urine'), dysmorphic RBCs, RBC casts"))
story.append(b("<b>2. Hypertension</b> — salt/water retention (RAAS activation + reduced GFR)"))
story.append(b("<b>3. Oliguria</b> — fluid retention, periorbital + lower limb edema"))
story.append(b("Sub-nephrotic proteinuria, azotemia (elevated Cr, BUN), flank pain, headache"))
story.append(b("<b>Hypertensive encephalopathy:</b> seizures, visual disturbances, altered consciousness"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("Bed rest; strict fluid balance; sodium restriction (<2 g/day)"))
story.append(b("<b>Furosemide</b> 1–2 mg/kg/day"))
story.append(b("<b>Antihypertensives:</b> nifedipine, amlodipine; IV labetalol/nitroprusside for hypertensive emergency"))
story.append(b("<b>Penicillin</b> ×10 days"))
story.append(b("<b>Dialysis</b> if: K+ >6, BUN >100, severe acidosis, uremic symptoms"))
story.append(note("Prognosis: excellent in children — >95% full recovery"))

# ══════════════════════════════════════════════════════════════════════════════
# Q20
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("20. APSGN with Nephrotic Syndrome: Clinic & Treatment"))
story.append(sp())
story.append(h2("Nephrotic Syndrome Criteria"))
story.append(make_table(
    [Paragraph('<b>Feature</b>', body_style), Paragraph('<b>Definition</b>', body_style)],
    [
        ['Proteinuria', '>3.5 g/day (adults); >40 mg/m²/h (children)'],
        ['Hypoalbuminemia', '<30 g/L'],
        ['Edema', 'Pitting: periorbital, ascites, pleural effusion, genital'],
        ['Hyperlipidemia', 'Elevated cholesterol, triglycerides'],
        ['Lipiduria', 'Fatty casts, oval fat bodies'],
    ],
    col_widths=[5*cm, 12*cm]
))
story.append(sp(6))
story.append(h2("Treatment"))
story.append(b("Fluid and sodium restriction; furosemide (caution in hypovolemia) + spironolactone"))
story.append(b("<b>Albumin 25% infusion</b> if severe hypoalbuminemia + hypovolemia → followed by furosemide"))
story.append(b("<b>Anticoagulation</b> (prophylactic heparin) if albumin <20 g/L (thromboembolism risk)"))
story.append(b("<b>Antibiotics:</b> penicillin"))
story.append(b("<b>Note:</b> Corticosteroids NOT routinely indicated in APSGN (usually self-limiting); differs from MCD"))

# ══════════════════════════════════════════════════════════════════════════════
# Q21
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("21. Acute & Chronic Pyelonephritis: Clinic & Diagnostics"))
story.append(sp())
story.append(h2("Acute Pyelonephritis — Clinic"))
story.append(b("<b>Etiology:</b> E. coli (80%), Klebsiella, Proteus, Enterococcus; ascending infection"))
story.append(b("High fever (>38.5°C), chills, rigors"))
story.append(b("Flank/loin pain (positive Pasternatsky sign — CVA tenderness)"))
story.append(b("LUTS: dysuria, frequency, urgency (if cystitis coexists)"))
story.append(b("Nausea, vomiting, malaise"))
story.append(b("<b>Infants:</b> non-specific — fever, poor feeding, vomiting, FTT, neonatal jaundice"))
story.append(sp())
story.append(h2("Chronic Pyelonephritis — Clinic"))
story.append(b("Recurrent/low-grade fever, flank discomfort, fatigue, hypertension"))
story.append(b("Polyuria, nocturia (tubular dysfunction); CKD in advanced disease"))
story.append(sp())
story.append(h2("Diagnostics"))
story.append(b("<b>Urinalysis:</b> pyuria (WBC >5/hpf), leukocyte casts (pathognomonic), bacteriuria, nitrites+"))
story.append(b("<b>Urine culture (gold standard):</b> >10⁵ CFU/mL"))
story.append(b("<b>CBC:</b> leukocytosis + left shift (acute); anemia (chronic)"))
story.append(b("<b>Imaging:</b> USS (enlarged/scarred kidney, hydronephrosis); DMSA scan (cortical scars — gold standard in children)"))
story.append(b("<b>MCUG:</b> vesicoureteral reflux in children; CT urography: stones, obstruction, abscess"))

# ══════════════════════════════════════════════════════════════════════════════
# Q22
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("22. Acute & Chronic Pyelonephritis: Treatment"))
story.append(sp())
story.append(h2("Acute Pyelonephritis"))
story.append(make_table(
    [Paragraph('<b>Setting</b>', body_style), Paragraph('<b>Regimen</b>', body_style)],
    [
        ['Outpatient (mild–moderate)', 'Ciprofloxacin 500 mg BID ×7d OR levofloxacin 750 mg OD ×5d OR cotrimoxazole ×14d'],
        ['Children', 'Cefixime, cotrimoxazole, or amox-clav ×10–14d'],
        ['Inpatient (severe)', 'IV ceftriaxone 1–2 g/day OR IV ampicillin + gentamicin → oral when improved (total 14d)'],
    ],
    col_widths=[5.5*cm, 11.5*cm]
))
story.append(sp(6))
story.append(b("<b>Supportive:</b> IV fluids, antipyretics, analgesia"))
story.append(b("<b>Drainage</b> if obstruction: percutaneous nephrostomy or ureteral stent"))
story.append(sp())
story.append(h2("VUR in Children"))
story.append(b("Grade I–III: prophylactic antibiotics (trimethoprim/nitrofurantoin), await spontaneous resolution"))
story.append(b("Grade IV–V: endoscopic injection or ureteral reimplantation"))
story.append(sp())
story.append(h2("Chronic Pyelonephritis"))
story.append(b("Identify/treat underlying cause (VUR, stones, obstruction, neurogenic bladder)"))
story.append(b("Long-term antibiotic prophylaxis; BP control (ACE inhibitors/ARBs — renoprotective)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q23
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("23. Diseases with Increased Bleeding: Classification & Hemostasis"))
story.append(sp())
story.append(h2("Mechanism of Hemostasis"))
story.append(b("<b>Primary:</b> Vascular injury → vasoconstriction → platelet adhesion (GPIb-vWF) → activation (TxA2, ADP) → aggregation (GPIIb/IIIa-fibrinogen) → platelet plug"))
story.append(b("<b>Secondary (coagulation cascade):</b>"))
story.append(b2("Extrinsic: TF + VIIa → Xa"))
story.append(b2("Intrinsic: XIIa → XIa → IXa + VIIIa → Xa"))
story.append(b2("Common: Xa + Va → thrombin → fibrinogen → fibrin (stabilized by XIIIa)"))
story.append(b("<b>Fibrinolysis:</b> Plasminogen → plasmin → fibrin degradation products"))
story.append(sp())
story.append(h2("Classification"))
story.append(make_table(
    [Paragraph('<b>Disorder</b>', body_style), Paragraph('<b>Platelet/Vessel</b>', body_style), Paragraph('<b>PT</b>', body_style), Paragraph('<b>aPTT</b>', body_style)],
    [
        ['Thrombocytopenia (ITP, TTP)', 'Low count', 'Normal', 'Normal'],
        ['Hemophilia A/B', 'Normal', 'Normal', 'Prolonged'],
        ['von Willebrand disease', 'Prolonged BT', 'Normal', 'Prolonged'],
        ['Hemorrhagic vasculitis', 'Vessel wall', 'Normal', 'Normal'],
        ['DIC', 'Thrombocytopenia', 'Prolonged', 'Prolonged'],
        ['Liver disease', 'Combined', 'Prolonged', 'Prolonged'],
    ],
    col_widths=[5*cm, 4.5*cm, 3*cm, 3*cm]
))
story.append(sp(6))
story.append(h2("Differential Approach"))
story.append(b("<b>Petechiae/purpura/mucocutaneous:</b> platelet disorder or vasculitis"))
story.append(b("<b>Deep hematomas/hemarthroses:</b> coagulation factor deficiency (hemophilia)"))
story.append(b("<b>Mixed:</b> vWD, DIC, liver disease"))

# ══════════════════════════════════════════════════════════════════════════════
# Q24
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("24. Hemophilia: Clinic, Diagnosis, Treatment"))
story.append(sp())
story.append(h2("Types & Severity"))
story.append(make_table(
    ['', Paragraph('<b>Severe</b>', body_style), Paragraph('<b>Moderate</b>', body_style), Paragraph('<b>Mild</b>', body_style)],
    [
        ['Factor level', '<1%', '1–5%', '5–40%'],
        ['Bleeding', 'Spontaneous', 'After minor trauma', 'After surgery/major trauma'],
    ],
    col_widths=[4*cm, 4.5*cm, 4.5*cm, 4*cm]
))
story.append(sp(6))
story.append(h2("Clinic"))
story.append(b("<b>Hemarthroses</b> (most characteristic): knee, elbow, ankle → hemophilic arthropathy"))
story.append(b("Deep tissue hematomas (iliopsoas → hip pain, femoral nerve palsy)"))
story.append(b("Mucosal bleeding (less common than platelet disorders)"))
story.append(b("<b>Intracranial hemorrhage</b> (life-threatening)"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("Prolonged <b>aPTT;</b> normal PT, TT, platelet count"))
story.append(b("<b>Factor VIII assay</b> (Hemophilia A) or <b>Factor IX assay</b> (Hemophilia B)"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>Factor replacement:</b> recombinant FVIII (Hem A) or FIX (Hem B) — on-demand or prophylactic"))
story.append(b("<b>DDAVP:</b> mild Hemophilia A only (releases stored vWF/FVIII)"))
story.append(b("<b>Tranexamic acid:</b> adjunct for mucosal bleeding"))
story.append(b("<b>Inhibitors (15–30% of severe Hem A):</b> rFVIIa (NovoSeven) or FEIBA; emicizumab (bispecific Ab)"))
story.append(b("<b>Avoid:</b> IM injections, aspirin/NSAIDs; joint protection (physiotherapy)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q25
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("25. Immune Thrombocytopenic Purpura (ITP)"))
story.append(sp())
story.append(h2("Etiology & Pathogenesis"))
story.append(b("Autoimmune: anti-platelet IgG (against GPIIb/IIIa or GPIb/IX) → splenic destruction + impaired production"))
story.append(b("Children: often preceded by viral infection 1–3 weeks prior"))
story.append(sp())
story.append(h2("Clinic"))
story.append(b("Sudden petechiae, purpura, ecchymoses (skin); epistaxis, gingival bleeding, menorrhagia"))
story.append(b("<b>ICH (rare <1% but most serious)</b>"))
story.append(b("<b>No splenomegaly, no lymphadenopathy</b> (distinguishes from leukemia/lymphoma)"))
story.append(b("Child is otherwise well (afebrile, no systemic symptoms)"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("CBC: isolated thrombocytopenia (<100 × 10⁹/L, often <20); normal or large platelets on smear"))
story.append(b("Normal PT, aPTT; bone marrow: increased megakaryocytes"))
story.append(b("Exclude secondary causes: ANA, HIV, HCV"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>Platelet >30 × 10⁹/L, no significant bleeding:</b> observe (>80% spontaneous remission in children)"))
story.append(b("<b>Active bleeding/platelet <20:</b> IV methylprednisolone 30 mg/kg/day ×3d OR oral prednisolone 4 mg/kg/day"))
story.append(b("<b>IVIG</b> 1 g/kg/day ×1–2d (rapid response; preferred if surgery needed)"))
story.append(b("<b>Chronic ITP (>12 months):</b> splenectomy, rituximab, TPO receptor agonists (eltrombopag, romiplostim)"))
story.append(sp())
story.append(h2("First Aid for Bleeding"))
story.append(b("Direct pressure; ice packs; epistaxis: pinch soft nose ×10–15 min, nasal packing if persists"))
story.append(b("Tranexamic acid for mucosal bleeding; avoid IM injections, aspirin/NSAIDs"))
story.append(b("<b>Platelet transfusion:</b> only for life-threatening bleeding (ICH); give with IVIG simultaneously"))

# ══════════════════════════════════════════════════════════════════════════════
# Q26
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("26. Hemorrhagic Vasculitis (Henoch-Schonlein Purpura / IgA Vasculitis)"))
story.append(sp())
story.append(h2("Etiology & Pathogenesis"))
story.append(b("IgA-mediated small vessel vasculitis; triggers: URTI (GAS, viral), drugs, foods, vaccinations"))
story.append(b("Peak age 2–11 years; most common systemic vasculitis in children"))
story.append(b("Elevated aberrantly glycosylated IgA1 → immune complexes → small vessel deposition → complement activation → vasculitis"))
story.append(sp())
story.append(h2("Classic Tetrad"))
story.append(b("<b>Palpable purpura</b> — non-thrombocytopenic; lower limbs and buttocks; gravity-dependent"))
story.append(b("<b>Arthritis/arthralgia</b> — knees, ankles; migratory, non-destructive"))
story.append(b("<b>GI involvement</b> — colicky abdominal pain (mesenteric vasculitis), nausea, bloody diarrhea; risk of intussusception"))
story.append(b("<b>Renal involvement</b> — hematuria, proteinuria (IgA nephropathy pattern) — most important for prognosis"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("Clinical (palpable purpura + ≥1 criterion); platelets <b>normal</b> (key!)"))
story.append(b("<b>Skin biopsy:</b> IgA deposits on IF (gold standard)"))
story.append(b("Urinalysis (hematuria, proteinuria), elevated IgA (50%), renal biopsy if significant nephritis"))
story.append(sp())
story.append(h2("Treatment"))
story.append(b("<b>Skin/joints only:</b> NSAIDs, rest, hydration; spontaneous resolution in weeks"))
story.append(b("<b>GI involvement:</b> prednisolone 1–2 mg/kg/day (reduces abdominal pain duration)"))
story.append(b("<b>Renal:</b> mild = monitor; significant proteinuria = ACE inhibitors + corticosteroids; severe nephritis = ± azathioprine/cyclophosphamide"))
story.append(note("Prognosis: excellent in most; renal disease determines long-term outcome (CKD in 5–10%)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q27
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("27. Leukemia in Children: Classification, Clinic, Diagnosis"))
story.append(sp())
story.append(h2("Classification"))
story.append(b("<b>ALL</b> (Acute Lymphoblastic Leukemia) — 80% of childhood leukemia; peak age 2–5 years"))
story.append(b("<b>AML</b> (Acute Myeloid Leukemia) — 15–20%"))
story.append(b("<b>CML</b> — rare; <b>CLL</b> — extremely rare in children"))
story.append(b("<b>ALL subtypes:</b>"))
story.append(b2("By immunophenotype: B-cell ALL (85%, CD19+, CD10+) or T-cell ALL (15%, mediastinal mass, older boys)"))
story.append(b2("Favorable cytogenetics: hyperdiploidy, t(12;21)/ETV6-RUNX1"))
story.append(b2("Unfavorable: Ph+ t(9;22)/BCR-ABL1, KMT2A rearrangement, hypodiploidy"))
story.append(b2("NCI risk: Standard (age 1–9, WBC <50,000) vs High (age <1 or >9, or WBC >50,000)"))
story.append(sp())
story.append(h2("Clinic"))
story.append(b("<b>Bone marrow failure:</b>"))
story.append(b2("Anemia: pallor, fatigue, tachycardia"))
story.append(b2("Thrombocytopenia: petechiae, purpura, mucosal bleeding"))
story.append(b2("Neutropenia: recurrent infections, fever"))
story.append(b("<b>Organ infiltration:</b>"))
story.append(b2("Lymphadenopathy (generalized)"))
story.append(b2("Hepatosplenomegaly"))
story.append(b2("Bone/joint pain — limp, refusal to walk (common presenting symptom!)"))
story.append(b2("Mediastinal mass (T-cell ALL — SVC syndrome, respiratory distress)"))
story.append(b2("CNS: headache, vomiting, cranial nerve palsies (CN VI most common), papilledema"))
story.append(b2("Testicular: painless enlargement"))
story.append(sp())
story.append(h2("Diagnosis"))
story.append(b("<b>CBC + smear:</b> anemia, thrombocytopenia, variable WBC, blast cells"))
story.append(b("<b>Bone marrow aspiration (gold standard):</b> >25% blasts + immunophenotyping (flow cytometry)"))
story.append(b("<b>Cytogenetics/FISH/PCR:</b> chromosomal analysis, translocation detection"))
story.append(b("<b>CSF analysis</b> (LP): CNS involvement"))
story.append(b("LDH elevated (tumor burden), uric acid elevated; CXR/CT (mediastinal mass)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q28
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("28. Leukemia in Children: Treatment"))
story.append(sp())
story.append(h2("ALL — Phases"))
story.append(make_table(
    [Paragraph('<b>Phase</b>', body_style), Paragraph('<b>Duration</b>', body_style), Paragraph('<b>Agents</b>', body_style)],
    [
        ['Remission Induction', '4–6 weeks', 'Glucocorticoid + Vincristine + L-Asparaginase (± Anthracycline for high-risk)'],
        ['CNS Prophylaxis', 'Throughout', 'Intrathecal methotrexate (± cytarabine, hydrocortisone); cranial RT largely replaced'],
        ['Consolidation', 'Months', 'High-dose methotrexate, 6-MP, cytarabine, cyclophosphamide (risk-adapted)'],
        ['Maintenance', '2–3 years', 'Oral 6-MP daily + methotrexate weekly; pulses of vincristine + steroid'],
    ],
    col_widths=[3.5*cm, 3*cm, 10.5*cm]
))
story.append(sp(6))
story.append(b("<b>Ph+ ALL:</b> add tyrosine kinase inhibitor (imatinib/dasatinib)"))
story.append(b("<b>Very high risk/relapsed:</b> allogeneic HSCT (bone marrow transplant)"))
story.append(b("<b>CAR-T cell therapy</b> (tisagenlecleucel) for relapsed/refractory B-cell ALL"))
story.append(sp())
story.append(h2("AML Treatment"))
story.append(b("Intensive chemotherapy: cytarabine + anthracycline ('7+3' regimen) → consolidation or HSCT"))
story.append(b("<b>AML-M3 (APL):</b> ATRA + arsenic trioxide (differentiation therapy — excellent prognosis)"))
story.append(sp())
story.append(h2("Supportive Care"))
story.append(b("<b>Tumor lysis syndrome prevention:</b> hyperhydration, allopurinol/rasburicase"))
story.append(b("<b>Infection prophylaxis:</b> antifungals, antivirals, cotrimoxazole (Pneumocystis)"))
story.append(b("Transfusions (RBCs, platelets); G-CSF post-transplant"))
story.append(note("Prognosis: ALL — 5-year OS >90% (standard risk); AML ~60–70%"))

# ══════════════════════════════════════════════════════════════════════════════
# Q29
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("29. Acute Allergic Reactions: Urticaria & Quincke's Edema"))
story.append(sp())
story.append(h2("Urticaria"))
story.append(b("<b>Clinic:</b> pruritic wheals (<24h each), erythematous, raised plaques; no residual skin changes"))
story.append(b("<b>Acute (<6 weeks):</b> usually IgE-mediated; triggers: foods, drugs (penicillin, NSAIDs), infections, insect stings"))
story.append(b("<b>Chronic (>6 weeks):</b> usually idiopathic/autoimmune; exclude thyroid disease, SLE"))
story.append(b("<b>Emergency care:</b>"))
story.append(b2("Mild–Moderate: oral non-sedating H1 antihistamine (cetirizine, loratadine, fexofenadine); up to 4× standard dose"))
story.append(b2("Severe/refractory: oral prednisolone 20–40 mg ×3–5d"))
story.append(b2("Chronic urticaria not responding: omalizumab (anti-IgE)"))
story.append(sp())
story.append(h2("Quincke's Edema (Angioedema)"))
story.append(b("Deep dermal/subcutaneous swelling; non-pitting, often non-pruritic"))
story.append(b("Location: face (lips, eyelids, tongue), throat, hands, genitalia"))
story.append(make_table(
    [Paragraph('<b>Type</b>', body_style), Paragraph('<b>Feature</b>', body_style), Paragraph('<b>Treatment</b>', body_style)],
    [
        ['Allergic/histaminergic', 'With urticaria; rapid onset', 'Epinephrine, antihistamines, steroids'],
        ['Hereditary (HAE)', 'No urticaria; recurrent; C1 inhibitor deficiency', 'C1-INH concentrate, icatibant (acute); danazol/tranexamic acid (prophylaxis)'],
        ['ACE inhibitor-induced', 'Bradykinin-mediated; no urticaria', 'Stop ACE inhibitor'],
    ],
    col_widths=[4*cm, 6*cm, 7*cm]
))
story.append(sp(6))
story.append(h2("Emergency Care (Laryngeal/Anaphylactic Angioedema)"))
story.append(b("<b>PRIORITY: Airway assessment</b> (tongue/throat involvement = asphyxia risk)"))
story.append(b("<b>Epinephrine 0.3–0.5 mg (1:1000) IM — LATERAL THIGH</b> (children: 0.01 mg/kg)"))
story.append(b("IV antihistamines (diphenhydramine), IV/IM corticosteroids (hydrocortisone 200–300 mg)"))
story.append(b("Prepare for airway management (intubation, cricothyrotomy)"))

# ══════════════════════════════════════════════════════════════════════════════
# Q30
# ══════════════════════════════════════════════════════════════════════════════
story.append(h1("30. Anaphylactic Shock"))
story.append(sp())
story.append(h2("Etiology"))
story.append(b("<b>Foods:</b> nuts (peanut, tree nuts), shellfish, fish, milk, eggs"))
story.append(b("<b>Drugs:</b> penicillin (most common), NSAIDs, muscle relaxants, IV contrast, vaccines"))
story.append(b("<b>Insect stings:</b> bee/wasp venom; latex, blood products; exercise-induced, idiopathic"))
story.append(sp())
story.append(h2("Pathophysiology"))
story.append(b("IgE crosslinking → mast cell/basophil degranulation → histamine, tryptase, PGs, leukotrienes → vasodilation, vascular permeability, bronchospasm"))
story.append(sp())
story.append(h2("Clinical Manifestations (multi-system, minutes)"))
story.append(make_table(
    [Paragraph('<b>System</b>', body_style), Paragraph('<b>Features</b>', body_style), Paragraph('<b>Frequency</b>', body_style)],
    [
        ['Cutaneous', 'Urticaria, angioedema, flushing, pruritus', '90%'],
        ['Respiratory', 'Bronchospasm (wheeze), stridor, hoarseness, dyspnea', '70%'],
        ['Cardiovascular', 'Hypotension, tachycardia, arrhythmia, collapse', '45%'],
        ['GI', 'Nausea, vomiting, diarrhea, crampy pain', '30–45%'],
        ['Neurological', 'Dizziness, syncope, anxiety, "sense of doom"', 'Variable'],
    ],
    col_widths=[4*cm, 10*cm, 3*cm]
))
story.append(sp(6))
story.append(h2("Emergency Care — Sequence"))
story.append(b("<b>1. STOP trigger</b> (stop infusion, remove stinger)"))
story.append(b("<b>2. EPINEPHRINE 0.3–0.5 mg (1:1000) IM — LATERAL THIGH</b> (children: 0.01 mg/kg, max 0.5 mg); repeat q5–15 min — THIS IS THE CORNERSTONE"))
story.append(b("<b>3. Position:</b> supine + legs elevated (or recovery position if vomiting; upright if respiratory distress)"))
story.append(b("<b>4.</b> Call for help; <b>high-flow oxygen</b> 10–15 L/min"))
story.append(b("<b>5. IV access + IV normal saline</b> 1–2 L bolus (adults); 10–20 mL/kg (children)"))
story.append(b("<b>6. Second-line (NEVER replace epinephrine):</b>"))
story.append(b2("H1 antihistamine: IV diphenhydramine or chlorphenamine (for urticaria; does NOT treat shock)"))
story.append(b2("H2 antihistamine: ranitidine/famotidine IV"))
story.append(b2("Glucocorticoids: hydrocortisone 200–300 mg IV (prevent biphasic reaction; NOT for acute shock)"))
story.append(b2("Salbutamol nebulization (for persistent bronchospasm)"))
story.append(b2("<b>Glucagon IV</b> (patients on beta-blockers — refractory to epinephrine)"))
story.append(b("<b>7. Vasopressors</b> (norepinephrine, dopamine) if refractory hypotension despite fluids + epinephrine"))
story.append(b("<b>8. Airway management:</b> intubation/surgical airway if laryngeal edema"))
story.append(sp())
story.append(h2("Observation & Discharge"))
story.append(b("Minimum 4–6h observation (biphasic risk up to 72h in 5–20%)"))
story.append(b("Discharge with 2 auto-injector epinephrine pens (EpiPen) + anaphylaxis action plan"))
story.append(b("Refer to allergist for trigger identification and desensitization"))
story.append(sp())
story.append(h2("Prognosis"))
story.append(b("Good if epinephrine given promptly; mortality <1% with rapid treatment"))
story.append(b("<b>Higher risk:</b> delayed epinephrine, severe initial reaction, asthma, cardiovascular disease, beta-blocker use"))

# BUILD
doc.build(story)
print(f"PDF created: {OUTPUT}")
Running Command

cd /tmp/workspace && python section3_pediatrics.py 2>&1

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Create a more concise quick reference version

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.